Methods and Means for Treatment of Osteoarthritis
The invention relates to the field of medicinal research, cartilage physiology and diseases involving the degeneration of cartilage tissue. More specifically, the invention relates to methods and means for identifying compounds that inhibit catabolic processes in chondrocytes and that decrease the degradation of cartilage and/or ECM. The invention also relates to the compounds that are useful in the treatment of osteoarthritis. The invention also relates to targets, the modulation of which results in a decrease in the degradation of ECM and/or cartilage and decrease inflammation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by the degradation of ECM and/or cartilage and inflammation.
The present application is a Divisional application of the National Stage Application U.S. Ser. No. 13/262,634 filed Oct. 1, 2011, claiming the priority of co-pending PCT Application No. PCT/EP2010/054412 filed Apr. 1, 2010, which in turn, claims priority from U.S. Provisional Application Ser. No. 61/211,740 filed Apr. 1, 2009. Applicants claim the benefits of 35 U.S.C. §120 as to the U.S. non-provisional National Stage application and the PCT application and priority under 35 U.S.C. §119 as to the said U.S. provisional application, and the entire disclosures of both applications are incorporated herein by reference in their entireties.
FIELD OF THE INVENTIONThe invention relates to the field of medicinal research, inflammation, cartilage physiology and diseases involving inflammation and/or the degeneration of cartilage tissue and/or extracellular matrix (ECM). More specifically, the present invention relates to agents, and methods for identifying compounds, which agents and compounds inhibit catabolic processes in chondrocytes and that would decrease the degradation of cartilage and/or extracellular matrix. The invention also relates to targets, the modulation of which results in a decrease in the degradation of ECM and/or cartilage and decrease inflammation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by the degradation of ECM and/or cartilage and inflammation. The invention also relates to the compounds that are useful in the treatment of osteoarthritis.
BACKGROUND OF THE INVENTIONCartilage is an avascular tissue of which chondrocytes are the main cellular component. The chondrocytes in normal articular cartilage occupy approximately 5% of the tissue volume, while the extra-cellular matrix makes up the remaining 95% of the tissue. The chondrocytes secrete the components of the matrix, mainly proteoglycans and collagens, which in turn supply the chondrocytes with an environment suitable for their survival under mechanical stress. In cartilage, collagen type II, together with the protein collagen type IX, is arranged in solid fibril-like structures which provide cartilage with great mechanical strength. The proteoglycans can absorb water and are responsible for the resilient and shock absorbing properties of the cartilage.
One of the functional roles of cartilage in the joint is to allow bones to articulate on each other smoothly. Loss of articular cartilage, therefore, causes the bones to rub against each other leading to pain and loss of mobility. The degradation of cartilage can have various causes. In inflammatory arthritides, as rheumatoid arthritis for example, cartilage degradation is caused by the secretion of proteases (e.g. collagenases) by inflamed tissues (the inflamed synovium for example). Cartilage degradation can also be the result of an injury of the cartilage, due to an accident or surgery, or exaggerated loading or ‘wear and tear’. Cartilage degradation may also be the result of an imbalance in cartilage synthesizing (anabolic) and cartilage degrading (catabolic) processes. The ability of cartilage tissue to regenerate after such insults is limited. Chondrocytes in injured cartilage often display reduced anabolic activity and/or increased catabolic activity. The limited ability of cartilage to self-repair after injury, disease, or surgery is a major limiting factor in rehabilitation of degrading joint surfaces and injury to meniscal cartilage.
The degeneration of cartilage is the hallmark of various diseases, among which rheumatoid arthritis and osteoarthritis are the most prominent.
Osteoarthritis (also referred to as OA, or wear-and-tear arthritis) is the most common form of arthritis and is characterized by loss of articular cartilage, often associated with hypertrophy of the bone and pain. The disease mainly affects hands and weight-bearing joints such as knees, hips and spines. This process thins the cartilage. When the surface area has disappeared due to the thinning, a grade I osteoarthritis is reached; when the tangential surface area has disappeared, grade II osteoarthritis is reached. There are further levels of degeneration and destruction, which affect the deep and the calcified cartilage layers that border with the subchondral bone. For an extensive review on osteoarthritis, we refer to Wieland et al., 2005.
Rheumatoid arthritis (RA) is a chronic joint degenerative disease, characterized by inflammation and destruction of the joint structures. When the disease is unchecked, it leads to substantial disability and pain due to loss of joint functionality and even premature death. The aim of an RA therapy, therefore, is not to slow down the disease but to attain remission in order to stop the joint destruction. Besides the severity of the disease outcome, the high prevalence of RA (˜0.8% of the adults are affected worldwide) means a high socio-economic impact. (For reviews on RA, we refer to Smolen and Steiner (2003); Lee and Weinblatt (2001); Choy and Panayi (2001); O'Dell (2004) and Firestein (2003)).
The clinical manifestations of the development of the osteoarthritis condition are: increased volume of the joint, pain, crepitation and functional disability that lead to pain and reduced mobility of the joints. When disease further develops, pain at rest emerges. If the condition persists without correction and/or therapy, the joint is destroyed leading to disability. Replacement surgery with total prosthesis is then required.
In mature articular cartilage, chondrocytes maintain the cartilage-specific matrix phenotype. Early signs of OA include progressive loss from articular cartilage of the proteoglycan aggrecan, due to damage to type II collagen. This protein represents the major structural collagen found in articular cartilage in healthy individuals. There is ordinarily a strict balance between the production of type II collagen and degradation of this protein by catabolic enzymes during normal remodeling of cartilage. Pathological conditions such as OA are characterized by a loss of this balance with increased proteolysis.
In general, elevated expression of MMPs is associated with the degradation of cartilage and/or extracellular matrix (ECM) but not all proteases are capable of degrading native collagen. Among the matrix metallo proteinases, MMP1, MMP8, MMP13 and MMP14 display the highest capacity for degrading collagen type II. Expression and contents of MMP-1 (collagenase-1) and MMP-13 (Mitchel et al., 1996; Shlopov et al., 1997), expression of MMP-8 (collagenase-2), and collagenase activity (Billinghurst et al., 1997, Dahlberg et al., 2000) are upregulated in human OA cartilage. In particular, MMP-13, also known as collagenase-3, is thought to play an important role in type II collagen degradation in articular cartilage and especially in OA (Billinghurst et al., 1997, Mitchell et al., 1996, Dahlberg et al., 2000, Billinghurst et al., 2000) as indicated by various observations. 1) The expression of MMP13 is increased in the cartilage of OA patients and of animals subjected to arthritogenic surgery like meniscectomy (Appleton et al., 2007) 2) The localization of MMP1 and MMP13 in arthritic cartilage appear to coincide with the location of cartilage destruction, as revealed by antibodies revealing neo-epitopes induced by cartilage cleavage. (Wu et al., 2002) 3) Overexpression of MMP13 in cartilage of transgenic mice lead to an OA-like cartilage destruction phenotype (Neuhold et al., 2001). 4) Type II collagen is the preferred substrate for MMP-13 (Billinghurst et al., 1997; Mitchell et al., 1996). Taken together, MMP13 is well-accepted as a key player in OA-induced cartilage and ECM degeneration.
Therapeutic methods for the correction of the articular cartilage lesions that appear during osteoarthritic disease have been developed, but so far none of them have been able to mediate the regeneration of articular cartilage in situ and in vivo.
Osteoarthritis is difficult to treat. At present, no cure is available and treatment focuses on relieving pain and preventing the affected joint from becoming deformed. Common treatments include the use of non-steroidal anti-inflammatory drugs (NSAIDs). Although dietary supplements such as chondroitin and glucosamine sulphate have been advocated as safe and effective options for the treatment or amelioration of osteoarthritis, a recent clinical trial revealed that both treatments did not reduce pain associated with osteoarthritis (Clegg et al., 2006). Taken together, no disease modifying osteoarthritic drugs are available.
In severe cases, joint replacement may be necessary. This is especially true for hips and knees. If a joint is extremely painful and cannot be replaced, it may be fused. This procedure stops the pain, but results in the permanent loss of joint function, making walking and bending difficult.
Another possible treatment is the transplantation of cultured autologous chondrocytes. Here, chondral cellular material is taken from the patient, sent to a laboratory where it is expanded. The material is then implanted in the damaged tissues to cover the tissue's defects.
Another treatment includes the intra-articular instillation of Hylan G-F 20 (e.g. Synvisc®, Hyalgan®, Artz®), a substance that improves temporarily the rheology of the synovial fluid, producing an almost immediate sensation of free movement and a marked reduction of pain.
Other reported methods include application of tendinous, periosteal, fascial, muscular or perichondral grafts; implantation of fibrin or cultured chondrocytes; implantation of synthetic matrices, such as collagen, carbon fiber; administration of electromagnetic fields. All of these have reported minimal and incomplete effects, resulting in a poor quality tissue that can neither support the weighted load nor allow the restoration of an articular function with normal movement.
Stimulation of the anabolic processes, blocking catabolic processes, or a combination of these two, may result in stabilization of the cartilage, and perhaps even reversion of the damage, and therefore prevent further progression of the disease.
The present invention relates to the relationship between the function of selected proteins identified by the present inventors (hereinafter referred to as “TARGETS”) and inhibition of cartilage and/or extra-cellular matrix (ECM) degradation and inhibition of inflammation.
SUMMARY OF THE INVENTIONThe present invention relates to a method for identifying compounds that reduce extra-cellular matrix (ECM) and/or cartilage degradation processes comprising contacting the compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42 (hereinafter “TARGETS”), or a functional fragment thereof, under conditions that allow said polypeptide to bind to the compound, and measuring a compound-polypeptide property related to the inhibition of ECM and/or cartilage degradation. In a particular embodiment the compound-polypeptide property is the level of inflammatory cytokines for example IL-1b, IL-6, IL-8, IL-11, TNFα and/or LIF. In a specific embodiment the compound-polypeptide property measured is expression levels of cartilage degradation proteins or proteases such as collagenase. In a particular embodiment the compound-polypeptide property measured is the expression levels of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4. In a specific embodiment the compound-polypeptide property measured is MMP13 expression levels.
Aspects of the present method include the in vitro assay of compounds using the polypeptide corresponding to a TARGET, or fragments thereof, such fragments being fragments of the amino acid sequences described by SEQ ID NO: 22-42, and cellular assays wherein TARGET inhibition is followed by observing indicators of efficacy including, for example, TARGET expression levels, TARGET enzymatic activity and/or MMP13 levels.
The present invention also relates to
-
- (1) expression inhibitory agents comprising a polynucleotide selected from the group of an antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), wherein said polynucleotide comprises a nucleic acid sequence complementary to, or engineered from, a naturally occurring polynucleotide sequence encoding a TARGET polypeptide said polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO: 22-42, and
- (2) pharmaceutical compositions comprising said agent(s), useful in the treatment, or prevention, of diseases characterized by ECM degradation and/or cartilage degradation such as osteoarthritis.
Another aspect of the invention is a method of treatment, or prevention, of a condition related to cartilage and/or ECM degeneration, bone and/or joint degradation, in a subject suffering or susceptible thereto, by administering a pharmaceutical composition comprising an effective TARGET-expression inhibiting amount of a expression-inhibitory agent or an effective TARGET activity inhibiting amount of a activity-inhibitory agent. In a particular embodiment the condition is osteoarthritis.
Another aspect of the invention is a method of treatment, or prevention, of a condition related to inflammation, in a subject suffering or susceptible thereto, by administering a pharmaceutical composition comprising an effective TARGET-expression inhibiting amount of a expression-inhibitory agent or an effective TARGET activity inhibiting amount of a activity-inhibitory agent.
A further aspect of the present invention is a method for diagnosis of a condition related to cartilage and/or ECM degeneration comprising measurement of indicators of levels of TARGET expression and/or activity in a subject.
A further aspect of the present invention is a method for diagnosis of a condition related to inflammation comprising measurement of indicators of levels of TARGET expression and/or activity in a subject.
Another aspect of this invention relates to the use of agents which inhibit a TARGET as disclosed herein in a therapeutic method, a pharmaceutical composition, and the manufacture of such composition, useful for the treatment of a disease involving cartilage and/or ECM degeneration. In particular, the present method relates to the use of the agents which inhibit a TARGET in the treatment of a disease characterized by joint degradation, and in particular, a disease characterized by abnormal MMP13 expression. The agents are useful for amelioration or treatment of a disease involving cartilage degradation, including but not limited to osteoarthritis, rheumatoid arthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome or costal chondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, endemic forms of arthritis like osteoarthritis deformans endemica, Mseleni disease, and Handigodu disease; degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, ankylosing spondylitis, congenital cartilage malformations, including hereditary chondrolysis, chondrodysplasias and pseudoachondrodysplasias, and congenital cartilage malformation related diseases for example microtia, anotia, and metaphyseal chondrodysplasia. In a particular embodiment the disease is selected from osteoarthritis, rheumatoid arthritis, and inflammatory arthritis. In a particular embodiment the disease is osteoarthritis.
Another aspect of this invention relates to the use of agents which inhibit a TARGET as disclosed herein in a therapeutic method, a pharmaceutical composition, and the manufacture of such composition, useful for the treatment of a disease involving inflammation, including but not limited to allergic airways disease (e.g. asthma, rhinitis), autoimmune diseases, transplant rejection, Crohn's disease, rheumatoid arthritis, psoriasis, juvenile idiopathic arthritis, colitis, and inflammatory bowel diseases.
In a further aspect the present invention also relates to methods for the in vitro production of cartilage tissue.
Another further aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective cartilage and/or ECM degradation-inhibiting amount of a TARGET inhibitor or its pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof in admixture with a pharmaceutically acceptable carrier. The present polynucleotides and TARGET inhibitor compounds are also useful for the manufacturing of a medicament for the treatment of conditions involving ECM degradation, cartilage degradation, and/or inflammation.
Furthermore, the invention also relates to diagnostic methods.
Other objects and advantages will become apparent from a consideration of the ensuing description taken in conjunction with the following illustrative drawings
The following terms are intended to have the meanings presented therewith below and are useful in understanding the description and intended scope of the present invention.
The term ‘agent’ means any molecule, including polypeptides, antibodies, polynucleotides, chemical compounds and small molecules. In particular the term agent includes compounds such as test compounds or drug candidate compounds.
The term ‘agonist’ refers to a ligand that stimulates the receptor the ligand binds to in the broadest sense.
As used herein, the term ‘antagonist’ is used to describe a compound that does not provoke a biological response itself upon binding to a receptor, but blocks or dampens agonist-mediated responses, or prevents or reduces agonist binding and, thereby, agonist-mediated responses.
The term ‘assay’ means any process used to measure a specific property of an agent. A ‘screening assay’ means a process used to characterize or select agents based upon their activity from a collection of agents.
The term ‘binding affinity’ is a property that describes how strongly two or more compounds associate with each other in a non-covalent relationship. Binding affinities can be characterized qualitatively (such as ‘strong’, ‘weak’, ‘high’, or ‘low’) or quantitatively (such as measuring the KD).
The term ‘carrier’ means a non-toxic material used in the formulation of pharmaceutical compositions to provide a medium, bulk and/or useable form to a pharmaceutical composition. A carrier may comprise one or more of such materials such as an excipient, stabilizer, or an aqueous pH buffered solution. Examples of physiologically acceptable carriers include aqueous or solid buffer ingredients including phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®.
The term ‘complex’ means the entity created when two or more compounds bind to, contact, or associate with each other.
The term ‘compound’ is used herein in the context of a ‘test compound’ or a ‘drug candidate compound’ described in connection with the assays of the present invention. As such, these compounds comprise organic or inorganic compounds, derived synthetically, recombinantly, or from natural sources.
The compounds include inorganic or organic compounds such as polynucleotides, lipids or hormone analogs. Other biopolymeric organic test compounds include peptides comprising from about 2 to about 40 amino acids and larger polypeptides comprising from about 40 to about 500 amino acids, including polypeptide ligands, enzymes, receptors, channels, antibodies or antibody conjugates.
The term ‘condition’ or ‘disease’ means the overt presentation of symptoms (i.e., illness) or the manifestation of abnormal clinical indicators (for example, biochemical indicators or diagnostic indicators). Alternatively, the term ‘disease’ refers to a genetic or environmental risk of or propensity for developing such symptoms or abnormal clinical indicators.
The term ‘contact’ or ‘contacting’ means bringing at least two moieties together, whether in an in vitro system or an in vivo system.
The term ‘derivatives of a polypeptide’ relates to those peptides, oligopeptides, polypeptides, proteins and enzymes that comprise a stretch of contiguous amino acid residues of the polypeptide and that retain a biological activity of the protein, for example, polypeptides that have amino acid mutations compared to the amino acid sequence of a naturally-occurring form of the polypeptide. A derivative may further comprise additional naturally occurring, altered, glycosylated, acylated or non-naturally occurring amino acid residues compared to the amino acid sequence of a naturally occurring form of the polypeptide. It may also contain one or more non-amino acid substituents, or heterologous amino acid substituents, compared to the amino acid sequence of a naturally occurring form of the polypeptide, for example a reporter molecule or other ligand, covalently or non-covalently bound to the amino acid sequence.
The term ‘derivatives of a polynucleotide’ relates to DNA-molecules, RNA-molecules, and oligonucleotides that comprise a stretch of nucleic acid residues of the polynucleotide, for example, polynucleotides that may have nucleic acid mutations as compared to the nucleic acid sequence of a naturally occurring form of the polynucleotide. A derivative may further comprise nucleic acids with modified backbones such as PNA, polysiloxane, and 2′-O-(2-methoxy)ethyl-phosphorothioate, non-naturally occurring nucleic acid residues, or one or more nucleic acid substituents, such as methyl-, thio-, sulphate, benzoyl-, phenyl-, amino-, propyl-, chloro-, and methanocarbanucleosides, or a reporter molecule to facilitate its detection.
The term ‘endogenous’ shall mean a material that a mammal naturally produces. Endogenous in reference to the term ‘protease’, ‘kinase’, ‘factor’, or ‘receptor’ shall mean that which is naturally produced by a mammal (for example, and not limitation, a human). In contrast, the term non-endogenous in this context shall mean that which is not naturally produced by a mammal (for example, and not limitation, a human). Both terms can be utilized to describe both in vivo and in vitro systems. For example, and without limitation, in a screening approach, the endogenous or non-endogenous TARGET may be in reference to an in vitro screening system. As a further example and not limitation, where the genome of a mammal has been manipulated to include a non-endogenous TARGET, screening of a candidate compound by means of an in vivo system is viable.
The term ‘expressible nucleic acid’ means a nucleic acid coding for a proteinaceous molecule, an RNA molecule, or a DNA molecule.
The term ‘expression’ comprises both endogenous expression and overexpression by transduction.
The term ‘expression inhibitory agent’ means a polynucleotide designed to interfere selectively with the transcription, translation and/or expression of a specific polypeptide or protein normally expressed within a cell. More particularly, ‘expression inhibitory agent’ comprises a DNA or RNA molecule that contains a nucleotide sequence identical to or complementary to at least about 15-30, particularly at least 17, sequential nucleotides within the polyribonucleotide sequence coding for a specific polypeptide or protein. Exemplary expression inhibitory molecules include ribozymes, double stranded siRNA molecules, self-complementary single-stranded siRNA molecules (shRNA), genetic antisense constructs, and synthetic RNA antisense molecules with modified stabilized backbones.
The term ‘fragment of a polynucleotide’ relates to oligonucleotides that comprise a stretch of contiguous nucleic acid residues that exhibit substantially a similar, but not necessarily identical, activity as the complete sequence. In a particular aspect, ‘fragment’ may refer to a oligonucleotide comprising a nucleic acid sequence of at least 5 nucleic acid residues (preferably, at least 10 nucleic acid residues, at least 15 nucleic acid residues, at least 20 nucleic acid residues, at least 25 nucleic acid residues, at least 40 nucleic acid residues, at least 50 nucleic acid residues, at least 60 nucleic residues, at least 70 nucleic acid residues, at least 80 nucleic acid residues, at least 90 nucleic acid residues, at least 100 nucleic acid residues, at least 125 nucleic acid residues, at least 150 nucleic acid residues, at least 175 nucleic acid residues, at least 200 nucleic acid residues, or at least 250 nucleic acid residues) of the nucleic acid sequence of said complete sequence.
The term ‘fragment of a polypeptide’ relates to peptides, oligopeptides, polypeptides, proteins, monomers, subunits and enzymes that comprise a stretch of contiguous amino acid residues, and exhibit substantially a similar, but not necessarily identical, functional or expression activity as the complete sequence. In a particular aspect, ‘fragment’ may refer to a peptide or polypeptide comprising an amino acid sequence of at least 5 amino acid residues (preferably, at least 10 amino acid residues, at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least 70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least 100 amino acid residues, at least 125 amino acid residues, at least 150 amino acid residues, at least 175 amino acid residues, at least 200 amino acid residues, or at least 250 amino acid residues) of the amino acid sequence of said complete sequence.
The term ‘hybridization’ means any process by which a strand of nucleic acid binds with a complementary strand through base pairing. The term ‘hybridization complex’ refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (for example, C0t, or R0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (for example, paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed). The term “stringent conditions” refers to conditions that permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, for example, formamide, temperature, and other conditions well known in the art. In particular, reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature can increase stringency. The term ‘standard hybridization conditions’ refers to salt and temperature conditions substantially equivalent to 5×SSC and 65° C. for both hybridization and wash. However, one skilled in the art will appreciate that such ‘standard hybridization conditions’ are dependent on particular conditions including the concentration of sodium and magnesium in the buffer, nucleotide sequence length and concentration, percent mismatch, percent formamide, and the like. Also important in the determination of “standard hybridization conditions” is whether the two sequences hybridizing are RNA-RNA, DNA-DNA or RNA-DNA. Such standard hybridization conditions are easily determined by one skilled in the art according to well known formulae, wherein hybridization is typically 10-20NC below the predicted or determined Tm with washes of higher stringency, if desired.
The term ‘inhibit’ or ‘inhibiting’, in relationship to the term ‘response’ means that a response is decreased or prevented in the presence of a compound as opposed to in the absence of the compound. The term inhibit or inhibiting more generally refers to the relative reduction, decrease, or prevention of an activity or measurable phenomenon, particularly in the presence of a compound versus in the absence of a compound.
The term ‘inhibition’ refers to the reduction, down regulation of a process or the elimination of a stimulus for a process, which results in the absence or minimization of the expression or activity of a protein or polypeptide.
The term ‘induction’ refers to the inducing, up-regulation, or stimulation of a process, which results in the expression or activity of a protein or polypeptide.
The term ‘ligand’ means a molecule, including an endogenous, naturally occurring or synthetic, non-natural molecules, specific for an endogenous, naturally occurring receptor.
The term ‘pharmaceutically acceptable salts’ refers to the non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds which inhibit the expression or activity of TARGETS as disclosed herein. These salts can be prepared in situ during the final isolation and purification of compounds useful in the present invention.
The term ‘polypeptide’ relates to proteins (such as TARGETS), proteinaceous molecules, fragments of proteins, monomers, subunits or portions of polymeric proteins, peptides, oligopeptides and enzymes (such as kinases, proteases, GPCR's etc.).
The term ‘polynucleotide’ means a polynucleic acid, in single or double stranded form, and in the sense or antisense orientation, complementary polynucleic acids that hybridize to a particular polynucleic acid under stringent conditions, and polynucleotides that are homologous in at least about 60 percent of its base pairs, and more particularly 70 percent of its base pairs are in common, most particularly 90 percent, and in a particular embodiment, 100 percent of its base pairs. The polynucleotides include polyribonucleic acids, polydeoxyribonucleic acids, and synthetic analogues thereof. It also includes nucleic acids with modified backbones such as peptide nucleic acid (PNA), polysiloxane, and 2′-O-(2-methoxy)ethylphosphorothioate. The polynucleotides are described by sequences that vary in length, that range from about 10 to about 5000 bases, particularly about 100 to about 4000 bases, more particularly about 250 to about 2500 bases. One polynucleotide embodiment comprises from about 10 to about 30 bases in length. A particular embodiment of polynucleotide is the polyribonucleotide of from about 17 to about 22 nucleotides, more commonly described as small interfering RNAs (siRNAs—double stranded siRNA molecules or self-complementary single-stranded siRNA molecules (shRNA)). Another particular embodiment are nucleic acids with modified backbones such as peptide nucleic acid (PNA), polysiloxane, and 2′-O-(2-methoxy)ethylphosphorothioate, or including non-naturally occurring nucleic acid residues, or one or more nucleic acid substituents, such as methyl-, thio-, sulphate, benzoyl-, phenyl-, amino-, propyl-, chloro-, and methanocarbanucleosides, or a reporter molecule to facilitate its detection. Polynucleotides herein are selected to be ‘substantially’ complementary to different strands of a particular target DNA sequence. This means that the polynucleotides must be sufficiently complementary to hybridize with their respective strands. Therefore, the polynucleotide sequence need not reflect the exact sequence of the target sequence. For example, a non-complementary nucleotide fragment may be attached to the 5′ end of the polynucleotide, with the remainder of the polynucleotide sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the polynucleotide, provided that the polynucleotide sequence has sufficient complementarity with the sequence of the strand to hybridize therewith under stringent conditions or to form the template for the synthesis of an extension product.
The term ‘preventing’ or ‘prevention’ refers to a reduction in risk of acquiring or developing a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop) in a subject that may be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset.
The term ‘prophylaxis’ is related to and encompassed in the term ‘prevention’, and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease. Non-limiting examples of prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization; and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.
The term ‘solvate’ means a physical association of a compound useful in this invention with one or more solvent molecules. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates and methanolates.
The term ‘subject’ includes humans and other mammals.
‘Therapeutically effective amount’ means that amount of a drug, compound, expression inhibitory agent, or pharmaceutical agent that will elicit the biological or medical response of a subject that is being sought by a medical doctor or other clinician.
The term ‘treating’ or ‘treatment’ of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof). In another embodiment ‘treating’ or ‘treatment’ refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, ‘treating’ or ‘treatment’ refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In a further embodiment, ‘treating’ or ‘treatment’ relates to slowing the progression of the disease.
The term “vectors” also relates to plasmids as well as to viral vectors, such as recombinant viruses, or the nucleic acid encoding the recombinant virus.
The term “vertebrate cells” means cells derived from animals having vertera structure, including fish, avian, reptilian, amphibian, marsupial, and mammalian species. Preferred cells are derived from mammalian species, and most preferred cells are human cells. Mammalian cells include feline, canine, bovine, equine, caprine, ovine, porcine murine, such as mice and rats, and rabbits.
The term ‘TARGET’ or ‘TARGETS’ means the protein(s) identified in accordance with the assays described herein and determined to be involved ECM and/or cartilage degraadation. The term TARGET or TARGETS includes and contemplates alternative species forms, isoforms, and variants, such as splice variants, allelic variants, alternate in frame exons, and alternative or premature termination or start sites, including known or recognized isoforms or variants thereof such as indicated in Table 1.
The term ‘disease characterized by ECM and/or cartilage degradation’ refers to a disease or condition which involves, results at least in part from, or includes a breakdown of the extracellular matrix or a breakdown in cartilage or wherein the degradation of, degeneration of, or loss of cartilage and/or ECM exceeds the generation or regeneration of cartilage and/or ECM. The term includes, but is not limited to, exemplary diseases selected from osteoarthritis, rheumatoid arthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome or costal chondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, endemic forms of arthritis like osteoarthritis deformans endemica, Mseleni disease, and Handigodu disease; degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, ankylosing spondylitis, congenital cartilage malformations, including hereditary chondrolysis, chondrodysplasias and pseudoachondrodysplasias, and congenital cartilage malformation related diseases for example microtia, anotia, and metaphyseal chondrodysplasia.
The term ‘disease characterized by inflammation’ refers to a disease which involves, results at least in part from or includes inflammation. The term includes, but is not limited to, exemplary diseases selected from allergic airways disease (e.g. asthma, rhinitis), autoimmune diseases, transplant rejection, Crohn's disease, rheumatoid arthritis, psoriasis, juvenile idiopathic arthritis, colitis, and inflammatory bowel diseases.
TargetsThe present invention is based on the present inventors' discovery that TARGETS are factors in the regulation of catabolic processes of chondrocytes, and in particular factors whose inhibition leads to a decrease in the catabolism of cartilage and/or ECM. Such a decrease may be monitored by following the expression of proteins related to cartilage and/or ECM degradation, for example but without limitation, MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4, in particular MMP13. The term “TARGET” or “TARGETS” means the proteins identified in accordance with the assay described below to be involved in the inhibition of ECM and/or cartilage degradation.
The TARGETS listed in Table 1 below were identified herein as involved in the pathway that regulates or modulates the catabolism of cartilage, particularly as involved in inhibiting the catabolism of cartilage, therefore, inhibitors of these TARGETS are able to inhibit degradation of cartilage and are of use in the prevention and/or treatment of diseases characterized by cartilage degradation.
The TARGETS are also factors in inflammatory processes, in particular they were identified as being involved in a reduction of the response to pro-inflammatory stimuli, particularly the response to IL1 stimulation, therefore inhibitors of these TARGETS are able to inhibit inflammatory processes and are of use in the prevention and/or treatment of diseases characterized by inflammation.
Therefore in one aspect, the present invention relates to a method for assaying for compounds that decrease ECM and/or cartilage degradation or inhibit inflammation, comprising contacting the compound with a polypeptide comprising an amino acid sequence of the polypeptides of SEQ ID NO: 22-42 (“TARGETS”) or a fragment thereof under conditions that allow said polypeptide to bind to the compound, and detecting the formation of a complex between the polypeptide and the compound. In particular said method is used to identify an agent that inhibits the degradation of cartilage. In particular said method may be used to identify drug candidate compounds that inhibit the degradation of cartilage via chondrocytes. In an alternative embodiment the method is used to identify an agent that inhibits inflammation. In an alternative embodiment the method is used to identify an agent that inhibits ECM degradation. One preferred means of measuring the complex formation is to determine the binding affinity of said compound to said polypeptide.
More particularly, the invention relates to a method for identifying an agent that reduces degradation of ECM and/or cartilage by chondrocytes, the method comprising:
-
- (a) contacting a population of chondrocyte cells with one or more compound(s) that exhibits binding affinity for a TARGET polypeptide, or fragment thereof, and
- (b) measuring a compound-polypeptide property related to the inhibition of ECM and/or cartilage degradation.
In a further aspect of the present invention said method is used to identify a compound that modulates the expression of or activity of one or more cartilage degrading enzyme, including for example MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4. In particular the inhibition of MMP13 expression may be measured.
In a further aspect of the present invention said method is used to identify a compound that modulates the expression or activity of one or more inflammatory cytokines, including for example IL-1b, IL-6, IL-8, IL-11, TNFα and/or LIF
In a further aspect, the present invention relates to a method for assaying for drug candidate compounds that inhibit cartilage and/or ECM degradation said method comprising contacting the compound with a polypeptide comprising an amino acid sequence selected from SEQ ID NO: 22-42, or a fragment thereof, under conditions that allow said compound to modulate the activity or expression of the polypeptide, and determining the activity or expression of the polypeptide. In particular said method may be used to identify drug candidate compounds capable of suppressing expression of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4, in particular suppressing the expression of MMP13. In particular said method may be to identify drug candidate compounds capable of suppressing the expression of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4, in particular MMP13, in normal human articular chondrocytes (NHACs). One particular means of measuring the activity or expression of the polypeptide is to determine the amount of said polypeptide using a polypeptide binding agent, such as an antibody, or to determine the activity of said polypeptide in a biological or biochemical measure, for instance the amount of phosphorylation of a target of a kinase polypeptide, or the amount of degradation by an enzyme or on an enzyme's substrate polypeptide.
The compound-polypeptide property referred to above is related to the inhibition of ECM and/or cartilage degradation, and is a measurable phenomenon chosen by the person of ordinary skill in the art. The measurable property may e.g. be the binding affinity for a peptide domain of the polypeptide TARGET or the level of any one of a number of biochemical marker levels of decreased catabolism by chondrocytes. Catabolic inhibition of chondrocytes can e.g. be measured by measuring the level of proteins and other molecules that are induced as part of the degradation pathway. In particular, the level of MMP13 may be measured.
In addition, compound-polypeptide properties related to the inhibition of ECM and/or cartilage degradation may be measured in normal human articular chondrocytes (NHACs), SW1353 (chondrosarcoma cells), fibroblasts (e.g. synovial fibroblasts), or differentiating mesenchymal stem cell cultures. To some extent, such properties could be measured in cells displaying expression of cartilage degrading enzymes, including MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4 expression. However, such properties are also measured in alternative cell systems. For example, in situ binding assays that determine the affinity of compounds to bind to polypeptides of the invention are performed using any cell type that expresses the polypeptide. Expression of the polypeptide is exogenous or endogenous. Furthermore, when the compound-polypeptide property is activation of a biological pathway, any cell that contains the pathway cellular components is used to measure the compound-polypeptide property. The cell may inherently contain these components or may be engineered to express one or more component or express a variant of a component which is labeled or measurable. For example, induction of MMP13 in response to IL-1 stimulation of NHACs is indicative of cartilage and/or ECM degradation. Specifically, cells can be engineered to contain a reporter molecule activated by the MMP13 promoters. In this way alternative cells can be used to measure a property indicative of inhibition of cartilage and/or ECM degradation.
In an additional aspect, the present invention relates to a method for assaying for drug candidate compounds that inhibit cartilage and/or ECM degradation, said method, comprising contacting the compound with a nucleic acid encoding a TARGET polypeptide, including a nucleic acid sequence selected from SEQ ID NO: 1-21, or a fragment thereof, under conditions that allow said nucleic acid to bind to or otherwise associate with the compound, and detecting the formation of a complex between the nucleic acid and the compound. In particular, said method may be used to identify drug candidate compounds able to reduce the level of proteins and other molecules that are induced as part of the degradation pathway. In particular, said method may be used to identify drug candidate compounds able to reduce the level of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4. In particular, said method may be used to identify drug candidate compounds able to reduce the level of MMP13. One particular means of measuring the complex formation is to determine the binding affinity of said compound to said nucleic acid or the presence of a complex by virtue of resistance to nucleases or by gel mobility assays. Alternatively, complex formation may be determined by inhibition of nucleic acid transcription or translation.
The invention relates to a method for identifying a compound that decreases the degradation of cartilage and/or ECM, said method comprising the steps of: culturing a population of cells expressing a polypeptide of any one of those listed in Table 1, or a functional fragment or derivative thereof; determining a first level of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4 expression in response to IL-1 stimulation in said population of cells; exposing said population of cells to a compound, or a mixture of compounds; determining the level of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4 expression in response to IL-1 stimulation in said population of cells during or after exposure of said population of cells to the compound, or the mixture of compounds; and identifying the compound that decreases the expression of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4 is predictive of a decrease in cartilage and/or ECM degradation. In a specific embodiment, the cartilage degrading enzyme measured in the method above is MMP13.
More particularly, the invention relates to a method for identifying an agent that reduces inflammation, the method comprising:
-
- (a) contacting a population of cells with one or more compound(s) that exhibits binding affinity for a TARGET polypeptide, or fragment thereof, and
- (b) measuring a compound-polypeptide property related to the inhibition of inflammation.
In one embodiment the compound-polypeptide property related to the inhibition of inflammation is the response of the cells to IL1 stimulation. In a further embodiment the agent is able to reduce the response of the cells to IL1 stimulation.
The invention also relates to a method for identifying a compound that decreases the expression and/or activity of any one of the polypeptides listed in Table 1, said method comprising the steps of: culturing a population of cells expressing said polypeptide, or a fragment, or a derivative thereof; determining a first level of expression and/or activity of said polypeptide; exposing said population of cells to a compound, or a mixture of compounds; determining the level of expression and/or activity of said polypeptide during or after exposure of said population of cells to the compound, or the mixture of compounds; and identifying the compound that decreases the expression and/or activity of said polypeptide. If the polypeptide activity is not readily measurable, the identification of the compound may benefit from an extra step comprising exposing said population of cells to an agonist of said polypeptide. Furthermore, the methods of the present invention may comprise the step of introducing a gene encoding any one of the polypeptides listed in Table 1, in said population of cells. For high-throughput purposes it may be beneficial to have the gene stably integrated in the genome of said cells.
In a preferred embodiment, the level of inhibition of cartilage and/or ECM degradation is determined by measuring the expression level of a marker gene, wherein a particular marker gene encodes MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4. In a specific embodiment, the expression and/or activity of MMP13 is measured. In a specific embodiment, the expression and/or activity of MMP13 is decreased.
In a particular embodiment of the invention, the TARGET polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID No: 22-42 as listed in Table 1. In an embodiment of the invention, the nucleic acid capable of encoding the TARGET polypeptide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-21 as listed in Table 1. Table 1 provides TARGET exemplary human nucleic acid and protein sequence, including recognized variants or isoforms where more than one accession number and SEQ ID NO: is indicated. Isoforms or variants of the TARGET(S) include nucleic acid or proteins with or utilizing alternate in frame exons, alternative splicing or splice variants, and alternative or premature termination variants.
The present invention provides in one particular embodiment methods for identifying novel compounds, wherein the polypeptide is a GPCR. If so, the expression and/or activity of said GPCR is preferably determined by measuring the level of a second messenger. Preferred second messengers are cyclic AMP, Ca2+ or both. Typically, the level of the second messenger is determined with a reporter gene under the control of a promoter that is responsive to the second messenger, wherein it is preferred that the promoter is a cyclic AMP-responsive promoter, an NF-KB responsive promoter, or a NF-AT responsive promoter, and wherein the reporter gene is selected from the group consisting of: alkaline phosphatase, GFP, eGFP, dGFP, luciferase and β-galactosidase. Exemplary TARGETs which are GPCRs are listed in Table 1 and include GPR34, GPR43, MC3R and EDG4.
In another particular embodiment, the invention provides methods for identifying novel compounds, wherein the polypeptide is a kinase or a phosphatase. Preferably, the activity of said kinase or phosphatase is determined by measuring the level of phosphorylation of a substrate of said kinase or phosphatase. Exemplary TARGETS which are kinases are listed in Table 1 and include MET, STK32B, MAP2K2, MAP4K1, EPHA5, and CSNK1G2, Preferred TARGETS which are kinases are selected from the group consisting of STK32B, EPHA5 and CSNK1G2. Particularly preferred TARGETS which are kinases are EPHA5 and CSNK1G2.
In yet another particular embodiment, the invention provides methods for identifying novel compounds, wherein the polypeptide is a protease. Preferably, the activity of said protease is measured by determining the level of cleavage of a substrate of said protease. Exemplary TARGETS which are proteases are listed in Table 1 and include ADAMTS6, and ADAM15.
In yet another particular embodiment, the invention provides methods for identifying novel compounds, wherein the polypeptide is an ion channel. An exemplary TARGET which is an ion channel is listed in Table 1, KCNN4.
Methods for determining second messenger levels, use of the reporter genes and second-messenger responsive promoters as well as phosphatase assays and protease assays are well known in the art and not further elaborated upon herein.
In a preferred embodiment, the compound that inhibits the polypeptide exhibits a binding affinity to the polypeptide of at most 10 micromolar.
In a preferred embodiment of the invention, the polypeptide TARGET comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42 (Table 1).
Depending on the choice of the skilled artisan, the present assay method may be designed to function as a series of measurements, each of which is designed to determine whether the drug candidate compound is indeed acting on the polypeptide to thereby inhibit the degradation of cartilage and/or ECM or to inhibit inflammation. For example, an assay designed to determine the binding affinity of a compound to the polypeptide, or fragment thereof, may be necessary, but not sufficient, to ascertain whether the test compound would be useful for decreasing ECM and/or cartilage degradation when administered to a subject, or alternatively to ascertain whether the test compound would be useful for decreasing inflammation. Nonetheless, such binding information would be useful in identifying a set of test compounds for use in an assay that would measure a different property, further up the biochemical pathway, such as the MMP13 assay described below or an assay using cartilage explants. Such second assay may be designed to confirm that the test compound, having binding affinity for the polypeptide, actually decreases the degradation of cartilage and/or ECM or reduces inflammation, in vitro or in vivo.
Suitable controls should always be in place to insure against false positive readings. In a particular embodiment of the present invention the screening method comprises the additional step of comparing the compound to a suitable control. In one embodiment, the control may be a cell or a sample that has not been in contact with the test compound. In an alternative embodiment, the control may be a cell that does not express the TARGET; for example in one aspect of such an embodiment the test cell may naturally express the TARGET and the control cell may have been contacted with an agent, e.g. an siRNA, which inhibits or prevents expression of the TARGET. Alternatively, in another aspect of such an embodiment, the cell in its native state does not express the TARGET and the test cell has been engineered so as to express the TARGET, so that in this embodiment, the control could be the untransformed native cell. The control may also or alternatively utilize a known mediator of inflammation or ECM and/or cartilage degradation, such as cells treated with cytokines e.g. IL1, TNFα, OSM, or other inflammatory mediators (e.g. LPA or reactive oxygen species), prostaglandins, or leukotrienes. Whilst exemplary controls are described herein, this should not be taken as limiting; it is within the scope of a person of skill in the art to select appropriate controls for the experimental conditions being used.
The order of taking these measurements is not believed to be critical to the practice of the present invention, which may be practiced in any order. For example, one may first perform a screening assay of a set of compounds for which no information is known respecting the compounds' binding affinity for the polypeptide. Alternatively, one may screen a set of compounds identified as having binding affinity for a polypeptide domain, or a class of compounds identified as being an inhibitor of the polypeptide. However, for the present assay to be meaningful to the ultimate use of the drug candidate compounds, a direct measurement of inflammation, ECM degradation and/or cartilage degradation will be valuable. Validation studies including controls, and measurements of binding affinity to the polypeptides of the invention are nonetheless useful in identifying a compound useful in any therapeutic or diagnostic application.
Analogous approaches based on art-recognized methods and assays may be applicable with respect to the TARGETS and compounds in any of various disease(s) characterized by cartilage and/or ECM degradation. An assay or assays may be designed to confirm that the test compound, having binding affinity for the TARGET, inhibits the degradation of cartilage and/or ECM. In one such method the expression and/or activity of a cartilage degradative enzyme such as a collagenase is measured. In one particular such method the expression and/or activity of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4 is measured. In one particular such method the expression and/or activity of MMP13 is measured.
Analogous approaches based on art-recognized methods and assays may be applicable with respect to the TARGETS and compounds in any of various disease(s) characterized by inflammation. An assay or assays may be designed to confirm that the test compound, having binding affinity for the TARGET, inhibits inflammation. In one such method the expression and/or activity of a cartilage degradative enzyme such as a collagenase is measured. In one particular such method the expression and/or activity of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4 is measured. In one particular such method the expression and/or activity of MMP13 is measured. In an alternative method the level of one or more inflammatory cytokines selected from IL-1b, IL-6, IL-8, IL-11, TNFα and/or LIF are measured.
The present assay method may be practiced in vitro, using one or more of the TARGET proteins, or fragments thereof, including monomers, portions or subunits of polymeric proteins, peptides, oligopeptides and enzymatically active portions thereof.
The binding affinity of the compound with the polypeptide TARGET can be measured by methods known in the art, such as using surface plasmon resonance biosensors (Biacore), by saturation binding analysis with a labeled compound (e.g. Scatchard and Lindmo analysis), by differential UV spectrophotometer, fluorescence polarization assay, Fluorometric Imaging Plate Reader (FLIPR®) system, Fluorescence resonance energy transfer, and Bioluminescence resonance energy transfer. The binding affinity of compounds can also be expressed in dissociation constant (Kd) or as IC50 or EC50. The IC50 represents the concentration of a compound that is required for 50% inhibition of binding of another ligand to the polypeptide. The EC50 represents the concentration required for obtaining 50% of the maximum effect in any assay that measures TARGET function. The dissociation constant, Kd, is a measure of how well a ligand binds to the polypeptide, it is equivalent to the ligand concentration required to saturate exactly half of the binding-sites on the polypeptide. Compounds with a high affinity binding have low Kd, IC50 and EC50 values, i.e. in the range of 100 nM to 1 pM; a moderate to low affinity binding relates to a high Kd, IC50 and EC50 values, i.e. in the micromolar range.
The present assay method may also be practiced in a cellular assay, A host cell expressing TARGET can be a cell with endogenous expression or a cell over-expressing the TARGET e.g. by transduction. When the endogenous expression of the polypeptide is not sufficient to determine a baseline that can easily be measured, one may use using host cells that over-express TARGET. Over-expression has the advantage that the level of the TARGET substrate end products is higher than the activity level by endogenous expression. Accordingly, measuring such levels using presently available techniques is easier. In one such cellular assay, the biological activity of TARGET may be measured by following the production of cartilage component synthesis.
One embodiment of the present method for identifying a compound that inhibits inflammation, ECM and/or cartilage degradation comprises culturing a population of cells expressing a TARGET polypeptide, or a fragment or derivative thereof; determining a first level of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4, in particular MMP13, expression and/or activity in said population of cells on activation of the population of cells (e.g. by stimulation using IL1); exposing said population of cells to a compound, or a mixture of compounds; determining a second level of expression or activity of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4, in particular MMP13, in said population of cells after the same activation, during or after exposure of said population of cells to said compound, or the mixture of said compounds; and identifying the compound(s) that suppress the expression and/or activity of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4, in particular MMP13. In a specific embodiment, the cells are chondrocytes. In a specific embodiment the cells are mammalian cells. In a specific embodiment the cells are human cells.
The expression and/or activity of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4 can be determined by methods known in the art such as the methods as described herein.
The present inventors identified TARGET genes involved in the inhibition of inflammation, cartilage and/or ECM degradation by using a ‘knock-down’ library. This type of library is a screen in which siRNA molecules are transduced into cells by recombinant adenoviruses, which siRNA molecules inhibit or repress the expression of a specific gene as well as expression and activity of the corresponding gene product in a cell. Each siRNA in a viral vector corresponds to a specific natural gene. By identifying a siRNA that inhibits the degradation of cartilage, as measured by suppression of the expression of MMP13, a direct correlation can be drawn between the specific gene expression and the pathway for inhibiting inflammation, cartilage and/or ECM degradation. The TARGET genes identified using the knock-down library (the protein expression products thereof herein referred to as “TARGET” polypeptides) are then used in the present inventive method for identifying compounds that can be used in the treatment of diseases associated with the inflammation or the degradation of ECM and/or cartilage. Indeed, shRNA compounds comprising the sequences listed in Table 2 (SEQ ID NOs: 43-57) inhibit the expression and/or activity of these TARGET genes and decrease the expression of MMP13, confirming the role of the TARGETS in the pathway leading to the degradation of cartilage and/or ECM or inflammation.
The present invention further relates to a method for identifying a compound that reduces inflammation and/or the degradation of cartilage and/or ECM, comprising:
-
- (a) contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42;
- (b) determining the binding affinity of the compound to the polypeptide;
- (c) contacting a population of mammalian cells expressing said polypeptide with the compound that exhibits a binding affinity of at least 10 micromolar; and
- (d) identifying a compound that reduces response to IL-1 or that reduces the synthesis of enzymes that act to degrade ECM and/or cartilage and/or related markers that indicate the presence of said enzymes.
In one aspect, the assay method includes contacting cells expressing said polypeptide with the compound that exhibits a binding affinity in the micromolar range. In an aspect, the binding affinity exhibited is at least 10 micromolar. In an aspect, the binding affinity is at least 1 micromolar. In an aspect, the binding affinity is at least 500 nanomolar.
The assay method may be based on the particular expression or activity of the TARGET polypeptide, including but not limited to an enzyme activity. Assays for the protease TARGETs ADAMTS6 (SEQ ID NO: 29) or ADAM15 (SEQ ID NOs: 31, 32, 33, 34, 35, or 36) may be based on protease activity or expression. Assays for the kinase TARGETs identified as MET (SEQ ID NO: 22), STK32B (SEQ ID NO: 23), MAP2K2 (SEQ ID NO: 28), MAP4K1 (SEQ ID NO: 37), EPHA5 (SEQ ID NOs: 39 or 40) and CSNK1G2 (SEQ ID NO: 41), may be based on kinase or phosphatase activity or expression, including but not limited to phosphorylation or dephosphorylation of a target protein. Assays for the GPCR TARGETs identified as GPR34 (SEQ ID NOs: 24, 25 or 26), GPR43 (SEQ ID NO: 27) MC3R (SEQ ID NO: 39) and EDG4 (SEQ ID NO: 42), may be based on GPCR activity or expression, including downstream mediators or activators. Assays for the ion channel TARGET identified as KCNN4 (SEQ ID NO: 30) may use techniques well known to those of skill in the art including classical patch clamping, high-throughput fluorescence based or tracer based assays which measure the ability of a compound to open or close an ion channel thereby changing the concentration of fluorescent dyes or tracers across a membrane or within a cell. The measurable phenomenon, activity or property may be selected or chosen by the skilled artisan. The person of ordinary skill in the art may select from any of a number of assay formats, systems or design one using his knowledge and expertise in the art.
Table 1 lists the TARGETS identified using applicants' knock-down library in the MMP13 assay described below, including the class of polypeptides identified. TARGETS have been identified in polypeptide classes including kinase, phophatase, protease, GPCR, and ion channel, for instance. Specific methods to determine the activity of a kinase by measuring the phosphorylation of a substrate by the kinase, which measurements are performed in the presence or absence of a compound, are well known in the art.
Specific methods to determine the inhibition by a compound by measuring the cleavage of the substrate by the polypeptide, which is a protease, are well known in the art. Classically, substrates are used in which a fluorescent group is linked to a quencher through a peptide sequence that is a substrate that can be cleaved by the target protease. Cleavage of the linker separates the fluorescent group and quencher, giving rise to an increase in fluorescence.
Ion channels are membrane protein complexes and their function is to facilitate the diffusion of ions across biological membranes. Membranes, or phospholipid bilayers, build a hydrophobic, low dielectric barrier to hydrophilic and charged molecules. Ion channels provide a high conducting, hydrophilic pathway across the hydrophobic interior of the membrane. The activity of an ion channel can be measured using classical patch clamping. High-throughput fluorescence-based or tracer-based assays are also widely available to measure ion channel activity. These fluorescent-based assays screen compounds on the basis of their ability to either open or close an ion channel thereby changing the concentration of specific fluorescent dyes across a membrane. In the case of the tracer based assay, the changes in concentration of the tracer within and outside the cell are measured by radioactivity measurement or gas absorption spectrometry.
G-protein coupled receptors (GPCR) are capable of activating an effector protein, resulting in changes in second messenger levels in the cell. The activity of a GPCR can be determined by measuring the activity level of such second messengers. Two exemplary important and useful second messengers in the cell are cyclic AMP (cAMP) and Ca2+. The second messenger activity levels can be measured by methods known to persons skilled in the art, either directly by ELISA or radioactive technologies or by using substrates that generate a fluorescent or luminescent signal when contacted with Ca2+ or indirectly by reporter gene analysis. The activity level of the one or more secondary messengers may typically be determined with a reporter gene controlled by a promoter, wherein the promoter is responsive to the second messenger. Promoters known and used in the art for such purposes are the cyclic-AMP responsive promoter that is responsive for the cyclic-AMP levels in the cell, and the NF-AT responsive promoter that is sensitive to cytoplasmic Ca2+-levels in the cell. The reporter gene typically has a gene product that is easily detectable. The reporter gene can either be stably infected or transiently transfected in the host cell. Useful reporter genes are alkaline phosphatase, enhanced green fluorescent protein, destabilized green fluorescent protein, luciferase and β-galactosidase.
It should be understood that the cells expressing the polypeptides may be cells which naturally express the polypeptides, or the cells may be transfected to express the polypeptides, as described above. Also, the cells may be transduced to overexpress the polypeptide, or may be transfected to express a non-endogenous form of the polypeptide, which can be differentially assayed or assessed.
In one particular embodiment the methods of the present invention further comprise the step of contacting the population of cells with an agonist of the polypeptide. This is useful in methods wherein the expression of the polypeptide in a certain chosen population of cells is too low for a proper detection of its activity. By using an agonist the polypeptide may be triggered, enabling a proper read-out if the compound inhibits the polypeptide. Similar considerations apply to the measurement of the release of inflammatory mediators. In a particular embodiment, the cells used in the present method are mammalian NHACs. The NHACs, in the assay contemplated, may be activated (e.g. by stimulation with IL1).
A method for identifying a compound that inhibits inflammation or cartilage and/or ECM degradation, comprising:
-
- (a) contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42, and fragments thereof; and
- (b) measuring a compound-polypeptide property related to cartilage degradation.
In one embodiment of the present invention the method relates to identifying a compound that inhibits the catabolic processes of chondrocytes.
In one embodiment of the present invention the compound-polypeptide property related to inflammation or cartilage and/or ECM degradation is binding affinity.
In one embodiment the compound-polypeptide property related to inflammation or cartilage and/or ECM degradation is the inhibition of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4 expression and/or activity.
In one embodiment the compound-polypeptide property related to inflammation or cartilage and/or ECM degradation is the inhibition of MMP13 expression and/or activity.
In one embodiment the compound-polypeptide property related to inflammation or cartilage and/or ECM degradation is the expression of inflammatory cytokines such as IL-1b, IL-6, IL-8, IL-11, TNFα and/or LIF.
In one embodiment of the present invention the compound-polypeptide property related to inflammation or cartilage and/or ECM degradation is the activity of said polypeptide. In particular, in one embodiment the compound inhibits the activity of said polypeptide.
In one embodiment of the present invention the compound-polypeptide property related to inflammation or cartilage and/or ECM degradation is the expression of said polypeptide. In particular, in one embodiment the compound inhibits the expression of said polypeptide.
The present invention further relates to a method for identifying a compound that inhibits inflammation or cartilage and/or ECM degradation, wherein said compound exhibits at least a moderate binding affinity to an amino acid selected from the group of SEQ ID NOS: 22-42, said method comprising:
-
- a) contacting a compound with a population of mammalian cells expressing a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 22-42, wherein the cells have been activated;
- b) determining the expression of MMP13 from said cells; and
- c) identifying the compound that inhibits inflammation or cartilage and/or ECM degradation as the compound which suppresses the release of MMP13 from the cells.
In one such method the cells are activated by being contacted with pro-inflammatory factors. In a specific embodiment of the method the pro-inflammatory factors are selected from TNF-alpha, IL-1, OSM (oncostatin M), IL6, endothelin, bradykinin, LPA, leukotrienes, prostaglandins, LPS (lipo poly saccharides) or other TLR ligands, or combinations thereof.
In one such method, the compound exhibits a binding affinity to an amino acid selected from the group of SEQ ID NOS: 22-42 of at least 10 micromolar.
The present invention further relates to a method for identifying a compound that inhibits inflammation or cartilage and/or ECM degradation, said method comprising:
-
- a) contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42;
- b) determining the binding affinity of the compound to the polypeptide;
- c) contacting a population of mammalian cells expressing said polypeptide with the compound that exhibits a binding affinity of at least 10 micromolar; and
- d) identifying the compound that inhibits inflammation or cartilage and/or ECM degradation.
The present invention further relates to a method for identifying a compound that inhibits inflammation or cartilage and/or ECM degradationsaid method comprising:
-
- a) contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42;
- b) determining the ability of the compound to inhibit the expression or activity of the polypeptide;
- c) contacting a population of mammalian cells expressing said polypeptide with the compound that significantly inhibits the expression or activity of the polypeptide; and
- d) identifying the compound that inhibits inflammation or cartilage and/or ECM degradation.
In a particular aspect of the present invention the methods described above include the additional step of comparing the compound to be tested to a control, where the control is a population of cells that have not been contacted with the test compound.
In a particular aspect of the present invention the methods described above include the additional step of comparing the compound to be tested to a control, where the control is a population of cells that do not express said polypeptide.
For high-throughput purposes, libraries of compounds may be used such as antibody fragment libraries, peptide phage display libraries, peptide libraries (e.g. LOPAP™, Sigma Aldrich), lipid libraries (BioMol), synthetic compound libraries (e.g. LOPAC™, Sigma Aldrich, BioFocus DPI) or natural compound libraries (Specs, TimTec, BioFocus DPI).
Preferred drug candidate compounds are low molecular weight compounds. Low molecular weight compounds, i.e. with a molecular weight of 500 Dalton or less, are likely to have good absorption and permeation in biological systems and are consequently more likely to be successful drug candidates than compounds with a molecular weight above 500 Dalton (Lipinski et al., (2001)). Peptides comprise another preferred class of drug candidate compounds. Peptides may be excellent drug candidates and there are multiple examples of commercially valuable peptides such as fertility hormones and platelet aggregation inhibitors. Natural products are another preferred class of drug candidate compound. Such compounds are found in and extracted from natural sources, and which may thereafter be synthesized. The lipids are another preferred class of drug candidate compound.
Another preferred class of drug candidate compounds is an antibody. The present invention also provides antibodies directed against a TARGET. These antibodies may be endogenously produced to bind to the TARGET within the cell, or added to the tissue to bind to TARGET polypeptide present outside the cell. These antibodies may be monoclonal antibodies or polyclonal antibodies. The present invention includes chimeric, single chain, domain antibodies, camelid antibodies, and humanized antibodies, as well as FAb fragments and the products of a FAb expression library, and Fv fragments and the products of an Fv expression library. The antibodies may be neutralizing antibodies or antibodies that inhibit the activity of the TARGET or that block or inhibit binding of a ligand to the TARGET or of the TARGET to another protein.
In certain embodiments, polyclonal antibodies may be used in the practice of the invention. The skilled artisan knows methods of preparing polyclonal antibodies. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. Antibodies may also be generated against the intact TARGET protein or polypeptide, or against a fragment, derivatives including conjugates, or other epitope of the TARGET protein or polypeptide, such as the TARGET embedded in a cellular membrane, or a library of antibody variable regions, such as a phage display library.
It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants that may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). One skilled in the art without undue experimentation may select the immunization protocol.
In some embodiments, the antibodies may be monoclonal antibodies. Monoclonal antibodies may be prepared using methods known in the art. The monoclonal antibodies of the present invention may be “humanized” to prevent the host from mounting an immune response to the antibodies. A “humanized antibody” is one in which the complementarity determining regions (CDRs) and/or other portions of the light and/or heavy variable domain framework are derived from a non-human immunoglobulin, but the remaining portions of the molecule are derived from one or more human immunoglobulins. Humanized antibodies also include antibodies characterized by a humanized heavy chain associated with a donor or acceptor unmodified light chain or a chimeric light chain, or vice versa. The humanization of antibodies may be accomplished by methods known in the art (see, e.g. Mark and Padlan, 1994). Transgenic animals may be used to express humanized antibodies.
Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, 1991; Marks et al., 1991). The techniques of Cole, et al. and Boerner, et al. are also available for the preparation of human monoclonal antibodies (Cole, et al., (1985); Boerner, et al., 1991). Techniques known in the art for the production of single chain antibodies can be adapted to produce single chain antibodies to the TARGET polypeptides and proteins of the present invention. The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain cross-linking. Alternatively; the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent cross-linking.
Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens and preferably for a cell-surface protein or receptor or receptor subunit. In the present case, one of the binding specificities is for one domain of the TARGET; the other one is for another domain of the same or different TARGET.
Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. Affinity chromatography steps usually accomplish the purification of the correct molecule. Similar procedures are disclosed in Trauneeker et al., 1991.
According to another preferred embodiment, the assay method uses a drug candidate compound identified as having a binding affinity for a TARGET, and/or has already been identified as having down-regulating activity such as antagonist activity vis-à-vis one or more TARGET.
In vivo animal models of arthritis or osteoarthritis or of inflammation or inflammatory diseases may be utilized by the skilled artisan to further or additionally screen, assess, and/or verify the agents or compounds identified in the present invention, including further assessing TARGET modulation in vivo. Such animal models include, but are not limited to, ulcerative colitis models, multiple sclerosis models (including EAE, lysolecithin-induced), arthritis models, allergic asthma models, airway inflammation models, and acute inflammation models. Osteoarthritis models include for example experimental osteoarthritis induced in rabbits after sectioning of the knee anterior cruciate ligament and in rats after tear of the medial collateral ligament.
The present invention further relates to a method for inducing anabolic stimulation of chondrocytes or reducing chondrocyte degradation comprising contacting said cells with an expression inhibitory agent comprising a polynucleotide sequence that complements at least about 17 nucleotides of the polyribonucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-21. In a preferred embodiment the expression-inhibitory agent comprises a polynucleotide sequence that complements a nucleotide sequence selected from the group consisting of SEQ ID NO: 43-57.
Another aspect of the present invention relates to a method for inhibiting inflammation or cartilage and/or ECM degradation, comprising contacting said cell with an expression-inhibiting agent that inhibits the translation in the cell of a polyribonucleotide encoding a TARGET polypeptide. A particular embodiment relates to a composition comprising a polynucleotide including at least one antisense strand that functions to pair the agent with the TARGET mRNA, and thereby down-regulate or block the expression of TARGET polypeptide. The inhibitory agent preferably comprises antisense polynucleotide, a ribozyme, or a small interfering RNA (siRNA), wherein said agent comprises a nucleic acid sequence complementary to, or engineered from, a naturally-occurring polynucleotide sequence encoding a portion of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42. In a preferred embodiment the expression-inhibiting agent is complementary to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-21. In an especially preferred embodiment the expression-inhibiting agent is complementary to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-57.
An embodiment of the present invention relates to a method wherein the expression-inhibiting agent is selected from the group consisting of antisense RNA, antisense oligodeoxynucleotide (ODN), a ribozyme that cleaves the polyribonucleotide coding for SEQ ID NO: 22-42, a small interfering RNA (siRNA, preferably shRNA,) that is sufficiently complementary to a portion of the polyribonucleotide coding for SEQ ID NO: 22-42, such that the siRNA, preferably shRNA, interferes with the translation of the TARGET polyribonucleotide to the TARGET polypeptide. Preferably the expression-inhibiting agent is an antisense RNA, ribozyme, antisense oligodeoxynucleotide, or siRNA, preferably shRNA, complementary to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-21. In an especially preferred embodiment the expression-inhibiting agent is complementary to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 43-57.
A special embodiment of the present invention relates to a method wherein the expression-inhibiting agent is a nucleic acid expressing the antisense RNA, antisense oligodeoxynucleotide (ODN), a ribozyme that cleaves the polyribonucleotide coding for SEQ ID NO: 22-42, a small interfering RNA (siRNA, preferably shRNA,) that is sufficiently complementary to a portion of the polyribonucleotide coding for SEQ ID NO: 22-42, such that the siRNA, preferably shRNA, interferes with the translation of the TARGET polyribonucleotide to the TARGET polypeptide. Preferably the nucleotide sequence is complementary to a polynucleotide selected from the group consisting of SEQ ID NO: 1-21. In an especially preferred embodiment nucleotide sequence is complementary to a polynucleotide selected from the group consisting of SEQ ID NO: 43-57.
The down regulation of gene expression using antisense nucleic acids can be achieved at the translational or transcriptional level. Antisense nucleic acids of the invention are preferably nucleic acid fragments capable of specifically hybridizing with all or part of a nucleic acid encoding a TARGET polypeptide or the corresponding messenger RNA. In addition, antisense nucleic acids may be designed which decrease expression of the nucleic acid sequence capable of encoding a TARGET polypeptide by inhibiting splicing of its primary transcript. Any length of antisense sequence is suitable for practice of the invention so long as it is capable of down-regulating or blocking expression of a nucleic acid coding for a TARGET. Preferably, the antisense sequence is at least about 17 nucleotides in length. The preparation and use of antisense nucleic acids, DNA encoding antisense RNAs and the use of oligo and genetic antisense is known in the art.
One embodiment of expression-inhibitory agent is a nucleic acid that is antisense to a nucleic acid comprising SEQ ID NO: 1-21. For example, an antisense nucleic acid (e.g. DNA) may be introduced into cells in vitro, or administered to a subject in vivo, as gene therapy to inhibit cellular expression of nucleic acids comprising SEQ ID NO: 1-21. Antisense oligonucleotides preferably comprise a sequence containing from about 17 to about 100 nucleotides and more preferably the antisense oligonucleotides comprise from about 18 to about 30 nucleotides. Antisense nucleic acids may be prepared from about 10 to about 30 contiguous nucleotides complementary to a nucleic acid sequence selected from the sequences of SEQ ID NO: 1-21.
The antisense nucleic acids are preferably oligonucleotides and may consist entirely of deoxyribo-nucleotides, modified deoxyribonucleotides, or some combination of both. The antisense nucleic acids can be synthetic oligonucleotides. The oligonucleotides may be chemically modified, if desired, to improve stability and/or selectivity. Since oligonucleotides are susceptible to degradation by intracellular nucleases, the modifications can include, for example, the use of a sulfur group to replace the free oxygen of the phosphodiester bond. This modification is called a phosphorothioate linkage. Phosphorothioate antisense oligonucleotides are water soluble, polyanionic, and resistant to endogenous nucleases. In addition, when a phosphorothioate antisense oligonucleotide hybridizes to its TARGET site, the RN202-315NA duplex activates the endogenous enzyme ribonuclease (RNase) H, which cleaves the mRNA component of the hybrid molecule.
In addition, antisense oligonucleotides with phosphoramidite and polyamide (peptide) linkages can be synthesized. These molecules should be very resistant to nuclease degradation. Furthermore, chemical groups can be added to the 2′ carbon of the sugar moiety and the 5 carbon (C-5) of pyrimidines to enhance stability and facilitate the binding of the antisense oligonucleotide to its TARGET site. Modifications may include 2′-deoxy, O-pentoxy, O-propoxy, O-methoxy, fluoro, methoxyethoxy phosphorothioates, modified bases, as well as other modifications known to those of skill in the art.
Another type of expression-inhibitory agent that reduces the levels of TARGETS is the ribozyme. Ribozymes are catalytic RNA molecules (RNA enzymes) that have separate catalytic and substrate binding domains. The substrate binding sequence combines by nucleotide complementarity and, possibly, non-hydrogen bond interactions with its TARGET sequence. The catalytic portion cleaves the TARGET RNA at a specific site. The substrate domain of a ribozyme can be engineered to direct it to a specified mRNA sequence. The ribozyme recognizes and then binds a TARGET mRNA through complementary base pairing. Once it is bound to the correct TARGET site, the ribozyme acts enzymatically to cut the TARGET mRNA. Cleavage of the mRNA by a ribozyme destroys its ability to direct synthesis of the corresponding polypeptide. Once the ribozyme has cleaved its TARGET sequence, it is released and can repeatedly bind and cleave at other mRNAs.
Ribozyme forms include a hammerhead motif, a hairpin motif, a hepatitis delta virus, group I intron or RNaseP RNA (in association with an RNA guide sequence) motif or Neurospora VS RNA motif. Ribozymes possessing a hammerhead or hairpin structure are readily prepared since these catalytic RNA molecules can be expressed within cells from eukaryotic promoters (Chen, et al., 1992). A ribozyme of the present invention can be expressed in eukaryotic cells from the appropriate DNA vector. If desired, the activity of the ribozyme may be augmented by its release from the primary transcript by a second ribozyme (Ventura, et al., 1993).
Ribozymes may be chemically synthesized by combining an oligodeoxyribonucleotide with a ribozyme catalytic domain (20 nucleotides) flanked by sequences that hybridize to the TARGET mRNA after transcription. The oligodeoxyribonucleotide is amplified by using the substrate binding sequences as primers. The amplification product is cloned into a eukaryotic expression vector.
Ribozymes are expressed from transcription units inserted into DNA, RNA, or viral vectors. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol (I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on nearby gene regulatory sequences. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Gao and Huang, 1993). It has been demonstrated that ribozymes expressed from these promoters can function in mammalian cells (Kashani-Sabet, et al., 1992).
A particularly preferred inhibitory agent is a small interfering RNA (siRNA, preferably shRNA). siRNA, preferably shRNA, mediates the post-transcriptional process of gene silencing by double stranded RNA (dsRNA) that is homologous in sequence to the silenced RNA. siRNA according to the present invention comprises a sense strand of 17-25 nucleotides complementary or homologous to a contiguous 17-25 nucleotide sequence selected from the group of sequences described in SEQ ID NO: 1-21, preferably from the group of sequences described in SEQ ID No: 43-57, and an antisense strand of 17-23 nucleotides complementary to the sense strand. Exemplary sequences are described as sequences complementary to SEQ ID NO: 43-57. The most preferred siRNA comprises sense and anti-sense strands that are 100 percent complementary to each other and the TARGET polynucleotide sequence. Preferably the siRNA further comprises a loop region linking the sense and the antisense strand.
A self-complementing single stranded siRNA molecule polynucleotide according to the present invention comprises a sense portion and an antisense portion connected by a loop region linker. Preferably, the loop region sequence is 4-30 nucleotides long, more preferably 5-15 nucleotides long and most preferably 8 or 12 nucleotides long. In a specific embodiment the linker sequence is UUGCUAUA. In an alternative specific embodiment the linker sequence is GUUUGCUAUAAC (SEQ ID NO: 58). Self-complementary single stranded siRNAs form hairpin loops and are more stable than ordinary dsRNA. In addition, they are more easily produced from vectors.
Analogous to antisense RNA, the siRNA can be modified to confirm resistance to nucleolytic degradation, or to enhance activity, or to enhance cellular distribution, or to enhance cellular uptake, such modifications may consist of modified internucleoside linkages, modified nucleic acid bases, modified sugars and/or chemical linkage the siRNA to one or more moieties or conjugates. The nucleotide sequences are selected according to siRNA designing rules that give an improved reduction of the TARGET sequences compared to nucleotide sequences that do not comply with these siRNA designing rules (For a discussion of these rules and examples of the preparation of siRNA, WO 2004/094636, and US 2003/0198627, are hereby incorporated by reference).
The present invention also relates to compositions, and methods using said compositions, comprising a DNA expression vector capable of expressing a polynucleotide capable of inhibiting the degradation of cartilage and described hereinabove as an expression inhibition agent.
A special aspect of these compositions and methods relates to the down-regulation or blocking of the expression of a TARGET polypeptide by the induced expression of a polynucleotide encoding an intracellular binding protein that is capable of selectively interacting with the TARGET polypeptide. An intracellular binding protein includes any protein capable of selectively interacting, or binding, with the polypeptide in the cell in which it is expressed and neutralizing the function of the polypeptide. Preferably, the intracellular binding protein is a neutralizing antibody or a fragment of a neutralizing antibody having binding affinity to an epitope of the TARGET polypeptide of SEQ ID NO: 22-42. More preferably, the intracellular binding protein is a single chain antibody.
A special embodiment of this composition comprises the expression-inhibiting agent selected from the group consisting of antisense RNA, antisense oligodeoxynucleotide (ODN), a ribozyme that cleaves the polyribonucleotide coding for SEQ ID NO: 22-42, and a small interfering RNA (siRNA) that is sufficiently homologous to a portion of the polyribonucleotide coding for SEQ ID NO: 22-42, such that the siRNA interferes with the translation of the TARGET polyribonucleotide to the TARGET polypeptide.
The polynucleotide expressing the expression-inhibiting agent is preferably included within a vector. The polynucleic acid is operably linked to signals enabling expression of the nucleic acid sequence and is introduced into a cell utilizing, preferably, recombinant vector constructs, which will express the antisense nucleic acid once the vector is introduced into the cell. A variety of viral-based systems are available, including adenoviral, retroviral, adeno-associated viral, lentiviral, herpes simplex viral or a sendaviral vector systems, and all may be used to introduce and express polynucleotide sequence for the expression-inhibiting agents in TARGET cells.
Preferably, the viral vectors used in the methods of the present invention are replication defective. Such replication defective vectors will usually lack at least one region that is necessary for the replication of the virus in the infected cell. These regions can either be eliminated (in whole or in part), or be rendered non-functional by any technique known to a person skilled in the art. These techniques include the total removal, substitution, partial deletion or addition of one or more bases to an essential (for replication) region. Such techniques may be performed in vitro (on the isolated DNA) or in situ, using the techniques of genetic manipulation or by treatment with mutagenic agents. Preferably, the replication defective virus retains the sequences of its genome, which are necessary for encapsidating, the viral particles.
In a preferred embodiment, the viral element is derived from an adenovirus. Preferably, the vehicle includes an adenoviral vector packaged into an adenoviral capsid, or a functional part, derivative, and/or analogue thereof. Adenovirus biology is also comparatively well known on the molecular level. Many tools for adenoviral vectors have been and continue to be developed, thus making an adenoviral capsid a preferred vehicle for incorporating in a library of the invention. An adenovirus is capable of infecting a wide variety of cells. However, different adenoviral serotypes have different preferences for cells. To combine and widen the TARGET cell population that an adenoviral capsid of the invention can enter in a preferred embodiment, the vehicle includes adenoviral fiber proteins from at least two adenoviruses. Preferred adenoviral fiber protein sequences are serotype 5, 17, 45 and 51. Techniques or construction and expression of these chimeric vectors are disclosed in US 2003/0180258 and US 2004/0071660, hereby incorporated by reference.
In a preferred embodiment, the nucleic acid derived from an adenovirus includes the nucleic acid encoding an adenoviral late protein or a functional part, derivative, and/or analogue thereof. An adenoviral late protein, for instance an adenoviral fiber protein, may be favorably used to TARGET the vehicle to a certain cell or to induce enhanced delivery of the vehicle to the cell. Preferably, the nucleic acid derived from an adenovirus encodes for essentially all adenoviral late proteins, enabling the formation of entire adenoviral capsids or functional parts, analogues, and/or derivatives thereof. Preferably, the nucleic acid derived from an adenovirus includes the nucleic acid encoding adenovirus E2A or a functional part, derivative, and/or analogue thereof. Preferably, the nucleic acid derived from an adenovirus includes the nucleic acid encoding at least one E4-region protein or a functional part, derivative, and/or analogue thereof, which facilitates, at least in part, replication of an adenoviral derived nucleic acid in a cell. The adenoviral vectors used in the examples of this application are exemplary of the vectors useful in the present method of treatment invention.
Certain embodiments of the present invention use retroviral vector systems. Retroviruses are integrating viruses that infect dividing cells, and their construction is known in the art. Retroviral vectors can be constructed from different types of retrovirus, such as, MoMuLV (“murine Moloney leukemia virus” MSV (“murine Moloney sarcoma virus”), HaSV (“Harvey sarcoma virus”); SNV (“spleen necrosis virus”); RSV (“Rous sarcoma virus”) and Friend virus. Lentiviral vector systems may also be used in the practice of the present invention.
In other embodiments of the present invention, adeno-associated viruses (“AAV”) are utilized. The AAV viruses are DNA viruses of relatively small size that integrate, in a stable and site-specific manner, into the genome of the infected cells. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies.
In the vector construction, the polynucleotide agents of the present invention may be linked to one or more regulatory regions. Selection of the appropriate regulatory region or regions is a routine matter, within the level of ordinary skill in the art. Regulatory regions include promoters, and may include enhancers, suppressors, etc.
Promoters that may be used in the expression vectors of the present invention include both constitutive promoters and regulated (inducible) promoters. The promoters may be prokaryotic or eukaryotic depending on the host. Among the prokaryotic (including bacteriophage) promoters useful for practice of this invention are lac, lacZ, T3, T7, lambda Pr, Pl, and trp promoters. Among the eukaryotic (including viral) promoters useful for practice of this invention are ubiquitous promoters (e.g. HPRT, vimentin, actin, tubulin), intermediate filament promoters (e.g. desmin, neurofilaments, keratin, GFAP), therapeutic gene promoters (e.g. MDR type, CFTR, factor VIII), tissue-specific promoters (e.g. actin promoter in smooth muscle cells, or Flt and Flk promoters active in endothelial cells), including animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift, et al. (1984) Cell 38:639-46; Ornitz, et al. (1986) Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, (1987) Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, (1985) Nature 315:115-22), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl, et al. (1984) Cell 38:647-58; Adames, et al. (1985) Nature 318:533-8; Alexander, et al. (1987) Mol. Cell. Biol. 7:1436-44), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder, et al. (1986) Cell 45:485-95), albumin gene control region which is active in liver (Pinkert, et al. (1987) Genes and Devel. 1:268-76), alpha-fetoprotein gene control region which is active in liver (Krumlauf, et al. (1985) Mol. Cell. Biol., 5:1639-48; Hammer, et al. (1987) Science 235:53-8), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey, et al. (1987) Genes and Devel., 1: 161-71), beta-globin gene control region which is active in myeloid cells (Mogram, et al. (1985) Nature 315:338-40; Kollias, et al. (1986) Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead, et al. (1987) Cell 48:703-12), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, (1985) Nature 314.283-6), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason, et al. (1986) Science 234:1372-8).
Other promoters which may be used in the practice of the invention include promoters which are preferentially activated in dividing cells, promoters which respond to a stimulus (e.g. steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators, cytomegalovirus immediate-early, retroviral LTR, metallothionein, SV-40, E1a, and MLP promoters.
Additional vector systems include the non-viral systems that facilitate introduction of polynucleotide agents into a patient. For example, a DNA vector encoding a desired sequence can be introduced in vivo by lipofection. Synthetic cationic lipids designed to limit the difficulties encountered with liposome-mediated transfection can be used to prepare liposomes for in vivo transfection of a gene encoding a marker (Felgner, et. al. (1987) Proc. Natl. Acad. Sci. USA 84:7413-7); see Mackey, et al. (1988) Proc. Natl. Acad. Sci. USA 85:8027-31; Ulmer, et al. (1993) Science 259:1745-8). The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes (Felgner and Ringold, (1989) Nature 337:387-8). Particularly useful lipid compounds and compositions for transfer of nucleic acids are described in WO 95/18863 and WO 96/17823, and in U.S. Pat. No. 5,459,127. The use of lipofection to introduce exogenous genes into the specific organs in vivo has certain practical advantages and directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, for example, pancreas, liver, kidney, and the brain. Lipids may be chemically coupled to other molecules for the purpose of targeting. Targeted peptides, e.g., hormones or neurotransmitters, and proteins for example, antibodies, or non-peptide molecules could be coupled to liposomes chemically. Other molecules are also useful for facilitating transfection of a nucleic acid in vivo, for example, a cationic oligopeptide (e.g. WO 95/21931), peptides derived from DNA binding proteins (e.g. WO 96/25508), or a cationic polymer (e.g. WO 95/21931).
It is also possible to introduce a DNA vector in vivo as a naked DNA plasmid (see U.S. Pat. No. 5,693,622, U.S. Pat. No. 5,589,466 and U.S. Pat. No. 5,580,859). Naked DNA vectors for therapeutic purposes can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (see, e.g., Wilson, et al. (1992) J. Biol. Chem. 267:963-7; Wu and Wu, (1988) J. Biol. Chem. 263:14621-4; Hartmut, et al. Canadian Patent Application No. 2,012,311, filed Mar. 15, 1990; Williams, et al (1991). Proc. Natl. Acad. Sci. USA 88:2726-30). Receptor-mediated DNA delivery approaches can also be used (Curiel, et al. (1992) Hum. Gene Ther. 3:147-54; Wu and Wu, (1987) J. Biol. Chem. 262:4429-32).
The present invention also provides biologically compatible, cartilage degradation-inhibiting compositions comprising an effective amount of one or more compounds identified as TARGET inhibitors, and/or the expression-inhibiting agents as described hereinabove.
A biologically compatible composition is a composition, that may be solid, liquid, gel, or other form, in which the compound, polynucleotide, vector, and antibody of the invention is maintained in an active form, e.g., in a form able to effect a biological activity. For example, a compound of the invention would have inverse agonist or antagonist activity on the TARGET; a nucleic acid would be able to replicate, translate a message, or hybridize to a complementary mRNA of a TARGET; a vector would be able to transfect a TARGET cell and expression the antisense, antibody, ribozyme or siRNA as described hereinabove; an antibody would bind a TARGET polypeptide domain.
A preferred biologically compatible composition is an aqueous solution that is buffered using, e.g., Tris, phosphate, or HEPES buffer, containing salt ions. Usually the concentration of salt ions will be similar to physiological levels. Biologically compatible solutions may include stabilizing agents and preservatives. In a more preferred embodiment, the biocompatible composition is a pharmaceutically acceptable composition. Such compositions can be formulated for administration by topical, oral, parenteral, intranasal, subcutaneous, and intraocular, routes. Parenteral administration is meant to include intravenous injection, intramuscular injection, intraarterial injection or infusion techniques. The composition may be administered parenterally in dosage unit formulations containing standard, well-known non-toxic physiologically acceptable carriers, adjuvants and vehicles as desired.
A particularly preferred embodiment of the present composition invention is a cartilage formation-enhancing pharmaceutical composition comprising a therapeutically effective amount of an expression-inhibiting agent as described hereinabove, in admixture with a pharmaceutically acceptable carrier. Another preferred embodiment is a pharmaceutical composition for the treatment or prevention of a condition involving inflammation or cartilage and/or ECM degradation, or a susceptibility to the condition, comprising an effective cartilage formation-enhancing amount of a TARGET antagonist or inverse agonist, its pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof in admixture with a pharmaceutically acceptable carrier. In one aspect the condition involves a systemic or local decrease in mean cartilage thickness.
Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient. Pharmaceutical compositions for oral use can be prepared by combining active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethyl-cellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinyl-pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.
Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
Preferred sterile injectable preparations can be a solution or suspension in a non-toxic parenterally acceptable solvent or diluent. Examples of pharmaceutically acceptable carriers are saline, buffered saline, isotonic saline (e.g. monosodium or disodium phosphate, sodium, potassium; calcium or magnesium chloride, or mixtures of such salts), Ringer's solution, dextrose, water, sterile water, glycerol, ethanol, and combinations thereof 1,3-butanediol and sterile fixed oils are conveniently employed as solvents or suspending media. Any bland fixed oil can be employed including synthetic mono- or di-glycerides. Fatty acids such as oleic acid also find use in the preparation of injectables.
The compounds or compositions of the invention may be combined for administration with or embedded in polymeric carrier(s), biodegradable or biomimetic matrices or in a scaffold. The carrier, matrix or scaffold may be of any material that will allow composition to be incorporated and expressed and will be compatible with the addition of cells or in the presence of cells. Preferably, the carrier matrix or scaffold is predominantly non-immunogenic and is biodegradable. Examples of biodegradable materials include, but are not limited to, polyglycolic acid (PGA), polylactic acid (PLA), hyaluronic acid, catgut suture material, gelatin, cellulose, nitrocellulose, collagen, albumin, fibrin, alginate, cotton, or other naturally-occurring biodegradable materials. It may be preferable to sterilize the matrix or scaffold material prior to administration or implantation, e.g., by treatment with ethylene oxide or by gamma irradiation or irradiation with an electron beam. In addition, a number of other materials may be used to form the scaffold or framework structure, including but not limited to: nylon (polyamides), dacron (polyesters), polystyrene, polypropylene, polyacrylates, polyvinyl compounds (e.g., polyvinylchloride), polycarbonate (PVC), polytetrafluorethylene (PTFE, teflon), thermanox (TPX), polymers of hydroxy acids such as polylactic acid (PLA), polyglycolic acid (PGA), and polylactic acid-glycolic acid (PLGA), polyorthoesters, polyanhydrides, polyphosphazenes, and a variety of polyhydroxyalkanoates, and combinations thereof. Matrices suitable include a polymeric mesh or sponge and a polymeric hydrogel. In the preferred embodiment, the matrix is biodegradable over a time period of less than a year, more preferably less than six months, most preferably over two to ten weeks. The polymer composition, as well as method of manufacture, can be used to determine the rate of degradation. For example, mixing increasing amounts of polylactic acid with polyglycolic acid decreases the degradation time. Meshes of polyglycolic acid that can be used can be obtained commercially, for instance, from surgical supply companies (e.g., Ethicon, N.J). A hydrogel is defined as a substance formed when an organic polymer (natural or synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel. In general, these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof. The composition medium may be a hydrogel, which is prepared from any biocompatible or non-cytotoxic homo- or hetero-polymer, such as a hydrophilic polyacrylic acid polymer that can act as a drug absorbing sponge. Certain of them, such as, in particular, those obtained from ethylene and/or propylene oxide are commercially available. A hydrogel can be deposited directly onto the surface of the tissue to be treated, for example during surgical intervention.
Embodiments of pharmaceutical compositions of the present invention comprise a replication defective recombinant viral vector encoding the polynucleotide inhibitory agent of the present invention and a transfection enhancer, such as poloxamer. An example of a poloxamer is Poloxamer 407, which is commercially available (BASF, Parsippany, N.J.) and is a non-toxic, biocompatible polyol. A poloxamer impregnated with recombinant viruses may be deposited directly on the surface of the tissue to be treated, for example during a surgical intervention. Poloxamer possesses essentially the same advantages as hydrogel while having a lower viscosity.
The active expression-inhibiting agents may also be entrapped in microcapsules prepared, for example, by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980) 16th edition, Osol, A. Ed.
Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™. (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C., resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S—S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
As defined above, therapeutically effective dose means that amount of protein, polynucleotide, peptide, or its antibodies, agonists or antagonists, which ameliorate the symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors which may be taken into account include the severity of the disease state, age, weight and gender of the patient; diet, desired duration of treatment, method of administration, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long acting pharmaceutical compositions might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
The pharmaceutical compositions according to this invention may be administered to a subject by a variety of methods. They may be added directly to TARGET tissues, complexed with cationic lipids, packaged within liposomes, or delivered to TARGET cells by other methods known in the art. Localized administration to the desired tissues may be done by direct injection, transdermal absorption, catheter, infusion pump or stent. The DNA, DNA/vehicle complexes, or the recombinant virus particles are locally administered to the site of treatment. Alternative routes of delivery include, but are not limited to, intravenous injection, intramuscular injection, subcutaneous injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. Examples of ribozyme delivery and administration are provided in Sullivan et al. WO 94/02595.
Antibodies according to the invention may be delivered as a bolus only, infused over time or both administered as a bolus and infused over time. Those skilled in the art may employ different formulations for polynucleotides than for proteins. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
As discussed hereinabove, recombinant viruses may be used to introduce DNA encoding polynucleotide agents useful in the present invention. Recombinant viruses according to the invention are generally formulated and administered in the form of doses of between about 104 and about 1014 pfu. In the case of AAVs and adenoviruses, doses of from about 106 to about 1011 pfu are preferably used. The term pfu (“plaque-forming unit”) corresponds to the infective power of a suspension of virions and is determined by infecting an appropriate cell culture and measuring the number of plaques formed. The techniques for determining the pfu titre of a viral solution are well documented in the prior art.
The present invention also provides methods of enhancing cartilage formation, which comprise the administration to said subject a therapeutically effective amount of an expression-inhibiting agent of the invention. A further aspect of the invention relates to a method of treating or preventing a disease involving chondrocyte anabolic stimulation, comprising administering to said subject a cartilage formation-enhancing pharmaceutical composition as described herein.
Examples of diseases involving degradation of ECM that are treatable using the means and methods of the present invention include, but are not limited to psoriatic arthritis, juvenile arthritis, early arthritis, reactive arthritis, osteoarthritis, ankylosing spondylitis. osteoporosis, muskulo skeletal diseases such as tendinitis and periodontal disease, cancer metastasis, airway diseases (COPD, asthma), renal and liver fibrosis, cardio-vascular diseases such as atherosclerosis and heart failure, and neurological diseases such as neuroinflammation and multiple sclerosis.
Examples of diseases involving degradation of cartilage that are treatable using the means and methods of the present invention include, but are not limited to osteoarthritis, rheumatoid arthritis, psoriatic arthritis, juvenile rheumatoid arthritis, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome or costal chondritis, fibromyalgia, osteochondritis, neurogenic or neuropathic arthritis, arthropathy, endemic forms of arthritis like osteoarthritis deformans endemica, Mseleni disease, and Handigodu disease; degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, and ankylosing spondylitis. Furthermore, people suffering from congenital cartilage malformations, including hereditary chondrolysis, chondrodysplasias and pseudoachondrodysplasias, are likely to benefit from programs that result in anabolic stimulation of chondrocytes, and these diseases therefore may also be treated by using the methods and means of the present invention. Non-limiting examples of congenital cartilage malformation related diseases are microtia, anotia, and metaphyseal chondrodysplasia.
In addition, as the identified targets do also inhibit IL-1 signal transduction, inhibitors of these targets could be of use in the treatment of inflammatory diseases. Examples of diseases involving inflammation that are treatable using the means and methods of the present invention include but are not limited to allergic airways disease (e.g. asthma, rhinitis), autoimmune diseases, transplant rejection, Crohn's disease, rheumatoid arthritis, psoriasis, juvenile idiopathic arthritis, colitis, and inflammatory bowel diseases.
In one aspect the present invention provides methods of preventing and/or treating disorders involving inflammation, ECM degradation and/or cartilage degradation, said methods comprising administering to a subject a therapeutically effective amount of an agent as disclosed herein. In a particular embodiment, the agent is selected from an expression-inhibiting agent and an antibody. In a particular embodiment the disorder is selected from osteoarthritis, rheumatoid arthritis, allergic airways disease (e.g. asthma, rhinitis), and autoimmune diseases. In a particular embodiment the disorder is osteoarthritis.
The invention also relates to the use of an agent as described above for the preparation of a medicament for treating or preventing a disease involving inflammation, ECM degradation and/or cartilage degradation. In a particular embodiment, the agent is selected from an expression-inhibiting agent and an antibody. In a particular embodiment of the present invention the disease is selected from osteoarthritis, rheumatoid arthritis, allergic airways disease (e.g. asthma, rhinitis), and autoimmune diseases. In a particular embodiment the disorder is osteoarthritis.
The present invention also provides a method of treating and/or preventing a disease involving inflammation, ECM degradation and/or cartilage degradation said method comprising administering, to a subject suffering from, or susceptible to, a disease involving cartilage degradation, a pharmaceutical composition or compound as described herein, particularly a therapeutically effective amount of an agent which inhibits the expression or activity of a TARGET as identified herein. In a particular embodiment the disorder is selected from osteoarthritis, rheumatoid arthritis, allergic airways disease (e.g. asthma, rhinitis), and autoimmune diseases. In a particular embodiment the disorder is osteoarthritis.
The invention also relates to an agent or a pharmaceutical composition as described above for use in the treatment and/or prevention of a disease involving inflammation, ECM degradation and/or cartilage degradation. In a particular embodiment the disorder is selected from osteoarthritis, rheumatoid arthritis, allergic airways disease (e.g. asthma, rhinitis), and autoimmune diseases. In a particular embodiment the disorder is osteoarthritis.
Administration of the agent or pharmaceutical composition of the present invention to the subject patient includes both self-administration and administration by another person. The patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk for diseases and medical conditions characterized by cartilage degradation. The agent of the present invention may be delivered to the subject patient orally, transdermally, via inhalation, injection, nasally, rectally or via a sustained release formulation.
Still another aspect of the invention relates to a method for diagnosing a pathological condition involving inflammation, ECM degradation and/or cartilage degradation, comprising determining the amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42 in a biological sample, and comparing the amount with the amount of the polypeptide in a healthy subject, wherein an increase of the amount of polypeptide compared to the healthy subject is indicative of the presence of the pathological condition. In a particular embodiment the disorder is selected from osteoarthritis, rheumatoid arthritis, allergic airways disease (e.g. asthma, rhinitis), and autoimmune diseases. In a particular embodiment the disorder is osteoarthritis.
Still another aspect of the invention relates to a method for diagnosing a pathological condition involving inflammation, ECM degradation and/or cartilage degradation, comprising determining the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22-42 in a biological sample, and comparing the activity with the activity of the polypeptide in a healthy subject, wherein an increase of the activity of polypeptide compared to the healthy subject is indicative of the presence of the pathological condition. Clearly, the activity and/or expression levels of the target genes as disclosed herein may have an effect on anabolic stimulation of chondrocytes. It remains to be determined to what level the activity should be elevated to diagnose for the disease. However, by comparing levels found in patients, individuals without symptoms and clearly healthy individuals the skilled person may easily determine these relevant levels. Since the skilled person is now aware which polypeptides should be monitored, the present invention provides novel tools for test assays for such diagnostics. A prominent disease that may be controlled, checked and diagnosed by using the knowledge provided by the present invention is osteoarthritis. In a particular embodiment the disorder is selected from osteoarthritis, rheumatoid arthritis, allergic airways disease (e.g. asthma, rhinitis), and autoimmune diseases. In a particular embodiment the disorder is osteoarthritis.
Still another aspect of the invention relates to a method for diagnosing a pathological condition involving inflammation, ECM degradation and/or cartilage degradation, comprising determining the nucleic acid sequence of at least one of the genes of SEQ ID NO: 1-21 within the genomic DNA of a subject; comparing the sequence with the nucleic acid sequence obtained from a database and/or a healthy subject; and identifying any difference(s) related to the onset or prevalence of the pathological conditions disclosed herein. Such differences may be further checked in in vitro assays applying similar marker genes as disclosed herein. Such assays will reveal the role of the gene or its encoded polypeptide in anabolic stimulation processes of chondrocytes. If such mutations are identified this knowledge can be further exploited in test-kits for diagnosis of similar diseases. In a particular embodiment the disorder is selected from osteoarthritis, rheumatoid arthritis, allergic airways disease (e.g. asthma, rhinitis), and autoimmune diseases. In a particular embodiment the disorder is osteoarthritis.
The polypeptides or the polynucleotides employed in the methods of the present invention may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. To perform the methods it is feasible to immobilize either the polypeptide of the present invention or the compound to facilitate separation of complexes from uncomplexed forms of the polypeptide, as well as to accommodate automation of the assay. Interaction (e.g., binding of) of the polypeptide of the present invention with a compound can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and microcentrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows the polypeptide to be bound to a matrix. For example, the polypeptide of the present invention can be “His” tagged, and subsequently adsorbed onto Ni-NTA microtitre plates, or ProtA fusions with the polypeptides of the present invention can be adsorbed to IgG, which are then combined with the cell lysates (e.g., (35S-labelled) and the candidate compound, and the mixture incubated under conditions favorable for complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the plates are washed to remove any unbound label, and the matrix is immobilized. The amount of radioactivity can be determined directly, or in the supernatant after dissociation of the complexes. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of the protein binding to the protein of the present invention quantitated from the gel using standard electrophoretic techniques.
Other techniques for immobilizing protein on matrices can also be used in the method of identifying compounds. For example, either the polypeptide of the present invention or the compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated protein molecules of the present invention can be prepared from biotin-NHS(N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with the polypeptides of the present invention but which do not interfere with binding of the polypeptide to the compound can be derivatized to the wells of the plate, and the polypeptide of the present invention can be trapped in the wells by antibody conjugation. As described above, preparations of a labeled candidate compound are incubated in the wells of the plate presenting the polypeptide of the present invention, and the amount of complex trapped in the well can be quantitated.
Another embodiment of the present invention relates to a method for the use of compounds which are able to ameliorate or to stabilize the properties of chondrocytes, chondrocyte progenitors, or mesenchymal stem cells used for autologous cell or cartilage transplantation, either during ex vivo culturing or after implantation. This amelioration can be the result of a reduced level of ECM and/or cartilage degrading proteases in or around the implant. For example a candidate compound may be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be via diffusion, timed-release bolus, or continuous administration.
The rate of ECM and/or cartilage degradation can typically be measured by determining the deposition of cartilage, or cartilage components, or cartilage-containing extra-cellular matrix produced by the chondrocytes, in the medium. A cell-based ELISA, enzymatic assays, or other general techniques known in the art can be used to measure cartilage components, like the ones described in Walsh G., Proteins: Biotechnology and Biochemistry. John Wiley and Sons, 2001.
The invention is further illustrated in the following figures and examples.
EXAMPLES Example 1 MMP13 Assay with NHACsAs described in the introduction, MMP13 has been identified in the osteoarthritis literature as one of the key players involved in catabolic events leading to the degradation of cartilage in the affected joints of osteoarthritic patients. Therefore, it was decided to initiate a functional genomics effort in order to identify factors that modulate the expression of MMP13 in primary human chondrocytes activated with a disease relevant trigger. This assay is further referred to herein as the “MMP13 assay”. The factors identified in this assay can be used as the basis for the development of novel therapies for osteoarthritis.
The MMP13 assay that has been developed for the screening of the SilenceSelect collection has the following distinctive features:
-
- The assay is run with primary human articular chondrocytes, but with minimal adaptations, could be used for any other source of primary chondrocytes, chondrocyte progenitors, or chondrocytic cell lines, or any cell that is capable of producing MMP13.
- The assay is run such that the primary human chondrocytes used are in an environment that resembles their normal environment (the cartilage matrix) as much as possible. The cells are grown in a three-dimensional culture, avoiding cell adhesion to the culture vessel.
- The assay has been optimized for use with arrayed adenoviral collections for functional genomics purposes.
- With minimal adaptations, the assay can also be used to screen compounds or compound collections
- The assay can be run in high throughput mode.
The MMP13 assay with normal human articular chondrocytes (NHACs) is described in more detail below. First, the protocol of the MMP13 ELISA that has been developed is described in section 1. Then the culture and maintenance of the primary chondrocytes is described in section 2. The screening protocol of the MMP13 assay with NHACs is described in section 3. The composition and performance of the control plate is shown in section 4. An example of the performance of the screening of the SilenceSelect collection is given in section 5.
The MMP13 assay in NHACs has been screened against an arrayed collection of 10946 different recombinant adenoviruses mediating the expression of shRNA's in NHACs. These shRNA's cause a reduction in expression levels of genes that contain homologous sequences by a mechanism known as RNA interference (RNAi). The 10946 Ad-siRNA's contained in the arrayed collection do target 6308 different transcripts. On average, every transcript is targeted by 2 to 3 independent, different Ad-siRNA's. The principle of the screening is illustrated in
Various antibodies and substrates were tested in order to develop an ELISA with sufficient sensitivity to detect the MMP13 amounts produced by cultured NHACs. A 384-well format ELISA for measurement of MMP13 was developed. Various primary antibodies were tested, as well as various ELISA protocols leading to the following validated protocol for measurement of MMP13 levels in 384 well plates. Black maxi sorb 384 well plates (Nunc 460518) are coated with 5 μg/mL anti-MMP13 antibody MAB511 (R&D Systems). The antibody is diluted in carbonate-bicarbonate coating buffer (1.59 g Na2CO3 (Sigma S-7795) and 2.93 g NaHCO3 (Sigma S-5761) in 1 L milliQ, adjusted to pH 9.6). After overnight incubation at 4° C., plates are washed three times with 100 μL PBST (80 g NaCl, 2 g KCl (Sigma), 11.5 g Na2HPO4.7H2O and 2 g KH2PO4 in 10 L milliQ; pH 7.4+0.05% Tween-20 (Sigma)) and blocked with 100 μL/well blocking buffer (5% non fat dry milk in PBS). After 2 hrs of incubation at room temperature, plates are washed three times with 100 μL PBST. The PBST is then removed and 35 μL of sample is transferred to the ELISA plates. After overnight incubation at 4° C., plates are washed three times with PBST and incubated for 1 hr at 37° C. with 35 μL/well 1.5 mM APMA. A 10 mM APMA stock solution (prepared one day before) is stored at 4° C. (35.18 mg APMA (Sigma A-9563) in 10 mL 0.1M NaOH (Merck 1.06469.1000)). The 10 mM APMA stock solution is diluted to 1.5 mM in APMA buffer (10×APMA buffer: 500 mM Tris (Roche 708976), 50 mM CaCl2 (Sigma C-5080), 500 μM ZnCl2 (Sigma Z-0173), 1.5 M NaCl (Calbiochem 567441), 0.5% Brij35 (Sigma 430 AG-6) and adjust to pH 7.0). After activation of MMP13 by APMA, plates are washed again three times with 100 μL PBST/well. OmniMMP Fluorescent substrate (Biomol P-126) is dissolved in OmniMMP buffer (10× OmniMMP buffer: 500 mM Hepes (Sigma H4034), 100 mM CaCl2 (Sigma C5080), 0.5% Brij35 (Sigma 430 AG-6; adjusted to pH 7.0) to a final concentration of 0.01 mM. 35 μL of this substrate is added to each well. After an overnight incubation at 37° C., the active MMP13 in the sample has cleaved the substrate and released fluorescence. Readout is performed on the EnVision (Perkin Elmer) using 320 nm excitation/405 nm emission filters.
1.2 Maintenance of the Primary ChondrocytesNormal human articular chondrocytes (NHACs) passage 1, were acquired from a commercial source (Cat No CC-2550, Cambrex Verviers, BE). For every experiment, a vial containing primary NHACs is thawed according to the manufacturers protocol and cells are cultured in monolayer in a T80 cell culture vessel in chondrocyte growth medium (CGM, Cat No CC3216, Cambrex, Verviers) under standard conditions (37° C., 5% CO2). When this culture reaches confluence, the cells are trypsinized according to the manufacturers protocol (using reagent pack Cat No CC-3233, Cambrex, Verviers, BE) and transferred to a new T175 culture vessel (1×10E+05 cells/T175 flask). When these cultures reached confluence, cells were trypsinized and subjected to the MMP13 assay. Therefore, the cells used for the MMP13 assay were only subcultured for 2 passages after thawing.
1.3. Screening ProcedureThe optimal screening protocol is as follows: 96 well tissue culture plates are coated with 50 μL of 1.5% of low melting point agarose prepared in DMEM-F12 medium supplemented with 5% of FBS and a mixture of 100 units/mL penicillin (Invitrogen) and 100 μg/mL streptomycin (Invitrogen) (this medium is further referred to as “assay medium”). NHACs were trypsinized and seeded in polypropylene 96 well plates (to avoid cell adhesion) at a density of 7500 cells/20 μL/well in DMEM-F12 medium containing 5% of FBS and a mixture of penicillin and streptomycin. The cells are then infected with an adenovirus mediating the expression of human Coxsackie/adenovirus receptor (hCAR) (at an MOI (multiplicity of infection, referring to the amount of viral particles used per cell in the assay) of approximately 250) in order to facilitate the subsequent infection with the Ad-siRNA viruses contained in the SilenceSelect collection. The human Coxsackie/adenovirus receptor is a coreceptor that is involved in the attachment of the adenovirus to the human cell membrane. Expression of this receptor in cells has been described to facilitate subsequent infection with adenoviruses, for example in T-cells (Schmidt et al., 2000). One day later, 12 μL Ad-siRNA virus from each well of the SilenceSelect® collection (WO 03/020931), stored in 384 well plates (estimated titer of 1×109 viral particles per mL) was transferred with the aid of a 96/384 channel dispenser to individual wells of the 96 well plates containing the NHACs. As the average titer of the adenoviral library is 1×109 Virus Particles/mL, this represents an average MOI of about 1600. After addition of the Ad-siRNA to the wells, an incubation step of one hour at 37° C. is performed. The infection is performed in an arrayed fashion as each well is infected with one individual type of Ad-siRNA from the SilenceSelect® collection. 40 μL of 0.8% low melting point agarose prepared in DMEMF12 medium supplemented with 8% FBS and a mixture of penicillin and streptomycin are then added to the wells. The content of the wells is mixed by pipetting up and down with a multichannel robot and 50 μL of the mixture is transferred to the 96 well plates coated with agarose. To speed up the solidification of the agarose, the plates are stored at 4° C. for approximately 15 minutes. 150 μL of assay medium is the added to the wells. The infected NHACs are then incubated for four days to allow the shRNA expression in the cells to reach sufficient levels and the gene silencing machinery in the cells to be fully primed and active. Four days after infection, the medium on the cells is refreshed with assay medium. One day later, the cells are triggered by addition of assay medium containing 10 ng/mL recombinant human IL1b. Two days after addition of the trigger, supernatant is collected and stored at −80° C. until subjected to the MMP13 ELISA. 35 μL of the supernatant are subjected to the MMP13 ELISA, which is performed in a 384 well plate format. The protocol applied for the high-throughput compatible ELISA is described in Example 1.1. The infection, medium replacement and medium collection steps were performed with a TECAN Freedom pipettor (Tecan Freedom 200 equipped with TeMO96, TeMO384 and RoMa, Tecan AG, Switzerland).
1.4. Performance of the Control PlateA 96 well control plate is generated to assess the quality of the assay. The control plates are produced in the same way as the SilenceSelect® collection. Multiple aliquots of this control plate are produced and stored at −80° C. For every screening run, a new aliquot of the screening plate is thawed and tested to allow the performance of all the screening runs to be compared. The composition of this plate is as follows. Wells are filled with control viruses that are produced under the same conditions as the SilenceSelect® adenoviral collection (WO 03/020931). This control plate contains four sets of positive control viruses (8 wells per positive control virus; P1 (Ad5-RIT1_v5_KD), P2 (Ad5-SLC26A8_v2_KD), P3 (Ad5-TRAF6_v4_KD), P4 (Ad5-NFKBIA_KI)), arranged in columns, interspaced with three sets of negative control viruses (16 wells per negative control virus; N1 (Ad5-Empty_KD), N2 (Ad5-M6PR_v1_KH), N3 (Ad5-LacZ_KI)). The negative controls viruses are tested either in presence of IL1 (8 wells) or in the absence of IL1 (8 wells). The positive control samples are selected either based on literature information (P3 (Ad5-TRAF6_v4_KD), P4 (Ad5-NFKBIA_KI)) or based on a preliminary screening of limited Ad-siRNA viruses (P1 (Ad5-RIT1_v5_KD), P2 (Ad5-SLC26A8_v2_KD)). TRAF6 is known to be required for the signal transduction downstream of IL1β (Cao et al., 1996), and over-expression of NFKBIA is known to inhibit NFKappaB, a transcription factor known to be required for the expression of MMP13 (Karin, 1999).
The control plate is run in parallel with and under the same conditions as the aliquot plates from the SilenceSelect® collection during the different screening runs. A representative example of the performance of the control plate tested with the screening protocol described above is shown in
In total, 10946 viruses of the SilenceSelect collection are screened in the MMP13 assay performed on primary NHACs cultured in agarose in 3D format, according to the protocol described in example 1.3. These 10946 viruses cover 6308 transcripts, reflecting the redundancy built in the SilenceSelect® collection. This redundancy results in most transcripts being targeted by multiple independent Ad-siRNAs contained within the SilenceSelect® collection. The data obtained during one of the screening batches are shown in
First, for every 384 well plate individually, the data for all samples are normalized and transformed into “normalized values” as follows. All 384 datapoints are listed and the 5% highest and 5% lowest MMP13 signals are removed from the list. Mean and standard deviation are then calculated over all samples of this reduced list and based on these mean and standard deviation, the normalized data are calculated by applying the formula: normalized value sample A=[(raw MMP13 signal sample A−mean)/(standard deviation)]. This transformation of the data per 384 well plate allows comparison of samples of different screening batches.
Then a threshold value is determined to allow hit calling as follows. For every screening batch, two 96 well control plates are tested on parallel with the samples from the SilenceSelect® collection and every control plate contains 3 negative control viruses (8 wells per negative control virus). The average and standard deviation of the MMP13 signal for the 3 negative controls contained in the control plates (3 times 16 wells=48 wells in total) is calculated. Based on this data, various threshold values are expressed in relation to the standard deviation by applying following formula: threshold value=[(average over the negative controls)−(“cutoff” times standard deviation over the negative controls)]. Various threshold values are then tested against the 48 negative controls. A cutoff is selected such that it defines a threshold value according to which less than 19% of the negative controls are lower than this threshold. Ad-siRNA viruses were nominated as primary hits if both datapoint (expressed as normalized values) for these Ad-siRNAs scored below the selected cutoff value in the primary screen.
In
The scheme shown in
In order to turn primary hits into confirmed hits, original hit Ad-siRNA's are repropagated twice independently in order to produce independent Ad-siRNA material. These repropagated viruses are then tested in the MMP13 ELISA on NHACs at 3 MOI's. The new virus material is screened at 3 MOI's because the repropagation material could generate virus material with a different titer as compared to the original primary hits contained in the SilenceSelect® collection. As 2 repropagations are tested at 3 MOI's, 6 datapoints are generated for every Ad-siRNA subjected to the ‘3 MOI rescreen’. Only the hits that score for at least 1 MOI for both repropagation materials are considered confirmed hits.
For the repropagation step, the primary hits are picked from the SilenceSelect collection and repropagated in 96 well plates together with positive and negative controls. A possible layout for 3 MOI rescreen runs is shown in
In a next step, the Ad-siRNAs contained in the repropagation plates are tested in the MMP13 assay on NHACs. For this test, the same protocol was used as the one described in Example 2 for the primary screening, with the only difference that 3 volumes of the repropagated viruses are used to infect the chondrocytes subjected to the MMP13 assay: i.e. 8 μL, 12 μL and 16 μL. All control wells except the 2 uninfected ones are then activated with IL1. In addition, the P6 and P7 controls are treated with staurosporin (5 μM final concentration) and brefeldin A (0.5 μg/mL final concentration). These compounds are added one day before the addition of the IL1 trigger as well as one day later together with the addition of the IL1 trigger. The aim of the staurosporin and Brefeldin A addition to the P6 and P7 control wells is to define the background MMP13 expression levels when secretion by the NHACs is completely blocked (brefeldin A) or when the cells are treated with a cytotoxic compound (staurosporin). The data of the 3 MOI rescreens are analyzed as follows.
First, for every plate, sample data are normalized using following formula:
Normalized MMP13 value sample A=[((raw MMP13 signal sample A)−(median MMP13 signal over the negative controls))/(standard deviation over the MMP13 signal of the negative controls)].
The same basis is applied to generate the normalized value for the positive controls:
Normalized MMP13 value positive controls=[((Median MMP13 signal over the positive controls))−(median MMP13 signal over the negative controls)/(standard deviation over the MMP13 signal of the negative controls)].
For the “3 MOI rescreens”, the positive controls are the wells treated with staurosporine and brefeldin A (P6 and P7), which are expected to reflect maximal inhibition of the IL1 induced MMP13 expression levels. Based on the normalized MMP13 values for the samples and the positive controls, the percentage inhibition is calculated for every sample by applying following formula: percentage inhibition sample A=[(Normalized MMP13 value sample A)/(Normalized MMP13 value positive controls)*100].
An example of the outcome of a 3 MOI rescreen is shown in
The 3 MOI rescreen data obtained for all 13 preferred targets are indicated in Table 3. This table shows the TARGETS identified as active in the “3 MOI rescreen”.
A typical example of the outcome of a rescreen experiment is displayed in
The quality and identity of hit Ad-siRNAs are checked by PCR and sequencing as described further. Target Ad-siRNAs are propagated using derivatives of PER.C6® cells (Crucell, Leiden, The Netherlands) in 96-well plates, followed by sequencing the siRNAs encoded by the target Ad-siRNA viruses. PER.C6/E2A cells are seeded in 96 well plates at a density of 40,000 cells/well in 180 μL of PER.C6/E2A medium. Cells are then incubated overnight at 39° C. in a 10% CO2 humidified incubator. One day later, cells are infected with 1 μL of crude cell lysate from SilenceSelect® stocks containing target Ad-siRNAs. Cells are incubated further at 34° C., 10% CO2 until appearance of a cytopathic effect (as revealed by the swelling and rounding up of the cells, typically at 7 days post infection). The supernatant is collected, and the virus crude lysate is treated with proteinase K by adding to 4 μL Lysis buffer (1× Expand High Fidelity buffer with MgCl2 (Roche Molecular Biochemicals, Cat. No 1332465) supplemented with 1 mg/mL proteinase K (Roche Molecular Biochemicals, Cat No 745 723) and 0.45% Tween-20 (Roche Molecular Biochemicals, Cat No 1335465) to 12 μL crude lysate in sterile PCR tubes. These tubes are incubated at 55° C. for 2 hours followed by a 15 minutes inactivation step at 95° C. For the PCR reaction, 1 μL lysate is added to a PCR master mix composed of 5 μL 10× Expand High Fidelity buffer with MgCl2, 0.5 μL of dNTP mix (10 mM for each dNTP), 1 μL of “Forward primer” (10 mM stock, sequence: 5′ CCG TTT ACG TGG AGA CTC GCC 3′ (SEQ. ID NO.: 59), 1 μL of “Reverse Primer” (10 mM stock, sequence: 5′ CCC CCA CCT TAT ATA TAT TCT TTC C) (SEQ. ID NO.: 60), 0.2 μL of Expand High Fidelity DNA polymerase (3.5 U/μL, Roche Molecular Biochemicals) and 41.3 μL of H2O.
PCR is performed in a PE Biosystems GeneAmp PCR system 9700 as follows: the PCR mixture (50 μL in total) is incubated at 95° C. for 5 minutes; each cycle runs at 95° C. for 15 sec., 55° C. for 30 sec., 68° C. for 4 minutes, and is repeated for 35 cycles. A final incubation at 68° C. is performed for 7 minutes. 5 μL of the PCR mixture is mixed with 2 μL of 6× gel loading buffer, loaded on a 0.8% agarose gel containing 0.5 μg/μL ethidium bromide to resolve the amplification products. The size of the amplified fragments is estimated from a standard DNA ladder loaded on the same gel. The expected size is approximately 500 bp. For sequencing analysis, the siRNA constructs expressed by the target adenoviruses are amplified by PCR using primers complementary to vector sequences flanking the SapI site of the pIPspAdapt6-U6 plasmid. The sequence of the PCR fragments is determined and compared with the expected sequence. All sequences are found to be identical to the expected sequence.
Example 4 On Target ValidationThe strengths and advantages of the siRNA technology are well-recognized and proved by the speed at which the technology has spread over the scientific community. Still the use of this technology asks for the required skills and knowledge as 1) siRNAs may nonspecifically target unrelated genes with only partial sequence-complementarity (off-target effects) and 2) the efficacy of siRNA's is difficult to predict (Pei et al., 2006). As such, it remains important to confirm the activity of a primary hit identified in a KD virus screen in an independent setting. Two approaches were taken to this end. First, a set of additional KD viruses were produced which were designed to reduce the expression of a certain gene through different target sequences. Second, synthetic siRNAs were purchased (Dharmacon) and used for target validation in the chondrocytic cell line SW1353.
4.1. On Target Analysis Using Additional KD VirusesA set of KD viruses designed to reduce the expression of selected preferred hits through different target sequences were produced. These KD viruses were subsequently arrayed on 96 well plates together with positive and negative control viruses. Identical controls were used as described for the repropagation plates described for the 3 MOI rescreen (Example 3). All additional different KD viruses targeting a particular hit were regrouped on a plate together with the original hit KD virus identified for this target during the primary screen. These plates were repropagated 2 times. Two copies of every repropagated plate was then tested in duplicate in 2 independent runs in the NHAC MMP13 assay as described above for the primary screen, using an MOI of 12 μl. As such, 8 datapoints were generated for every KD virus. The data were analysed as described above for the 3 MOI rescreen (Example 3), converting the data to % inhibition. KD viruses giving rise to a reduction of the MMP13 levels of 35% for 4 out of the 8 datapoints generated were considered validated in this assay. As such, 1 additional KD virus having the capacity to reduce IL1_induced MMP13 expression levels in NHACs was identified for the following targets: ADAM15, GPR34, EPHA5, MAP2K2, MET, GPR43, 2 additional KD viruses were identified for ADAMTS6, 3 for STK32B and 4 for MC3R.
4.2. On Target Analysis Using Synthetic siRNA
The purpose of this experiment was to further validate adenoviral shRNA mediated KD effects on IL1 triggered MMP13 release using synthetic siRNA duplexes. The validation was done in a chondrosarcoma SW1353 cell line that was previously shown to upregulate MMP13 expression in response to IL1 triggering.
4.2.1 MaterialsHuman chondrosarcoma SW1353 cells (Cat. No. HTB-94, ATCC) are grown in a humidified 5% CO2 incubator at 37° C. in DMEM (Cat. No. 41966-029, Gibco) supplemented with 10% heat-inactivated FBS (Hyclone) and 1× Penicillin/Streptomycin (Cat. No. 15140-122, Gibco) and subcultured (1:5 split ratio) twice a week after trypsinization.
Ready-to-use gene silencing siRNA duplexes for genes of interest may be obtained from Dharmacon. siGENOME SMARTpool (or ON-TARGETplus set of 4) lyophilized stock reagents are reconstituted in 1× siRNA Buffer (Cat. No. B-002000-UB-015, Dharmacon) to achieve 20 μM concentrations and aliquots are stored at −20° C.
4.2.2 ProceduresiRNA duplexes are delivered into the SW1353 cells under optimized conditions. SW1353 cells are plated in 96-well plates (Nunc) at 10 000 cells/100 μL cell culture medium 24 hours prior to transfection. Cells are transfected with the siRNA reagents (30 nM or 10 nM final concentration) using INTERFERin™ (Cat. No. 409-10, Polyplus-transfection) at a final concentration of 1 μL/well, essentially according to the manufacturers instructions. In brief, the siRNA stock reagent is diluted in 50 μL serum-free OptiMEM (Cat. No. 51985-026, Gibco) and 1 μL INTERFERin™ reagent is added followed by immediate homogenization for 10 sec and incubation at room temperature for 10-45 minutes to allow INTERFERin™/siRNA complexes to form. During complex formation the medium on top of the SW1353 cells is replaced with 100 μL pre-warmed cell culture medium containing no antibiotics. 50 μL of the formed INTERFERin™/siRNA mix is then added to the cells and plates are returned to the incubator at 37° C. and 5% CO2.
After 72 hr, the medium on top of the cells is removed and replaced with 100 μL pre-warmed culture medium containing 10 ng/mL recombinant human IL1β (Cat. No. 200-01B, PeproTech) and 25 ng/mL recombinant human OSM (Cat. No. 295-0M, R&D Systems). Culture medium is DMEM/F12 (Cat. No. 11320-074, Gibco) containing 5% heat-inactivated FBS and 1× Penicillin/Streptomycin.
24 hr after addition of the cytokines, the supernatant is collected and stored at −80° C. for later analysis of appropriate dilutions in the MMP13 ELISA (see example 1), MMP1 ELISA (as described in WO 2006/040357) and TIMP2 ELISA (as described in WO 2006/040357). As TIMP2 levels are not influenced by the addition of the trigger, changes in amount of TIMP2 secreted into the supernatant are used to assess the effect of siRNA gene-specific duplex transfection on cell viability/secretion.
The effect of siRNA duplex delivery for genes of interest on IL1/OSM mediated upregulation of MMP13 and MMP1 may be assessed in two independent experiments. In each experiment transfection of siRNA duplexes is performed in duplicate at two siRNA concentration (10 nM and 30 nM). SMARTpool reagents targeting the human MMP1 (siGENOME SMARTpool siRNA MMP1), and one out of 4 selected individual siRNA duplexes targeting the human TRAF6 gene (siGENOME SMARTpool siRNA set of 4) and MMP13 gene (siGENOME SMARTpool set of 4) are used as positive controls. Cells transfected with the siCONTROL Non-Targeting siRNA pool or with the GL2.2 duplex targeting luciferase at 30 nM and/or 10 nM are used as negative controls. For MMP1 analysis, negative controls include both siRNA reagents at the two concentrations. For MMP13 analysis, negative controls include the non-targeting siRNA reagent at 30 nM and 10 nM and the GL2.2 duplex at 10 nM. Additional wells transfected with the GL2.2 control that are left unstimulated are included as non-triggered controls. Positive, negative and non-triggered controls are included on each 96-well plate. The collected supernatant of 4 different 96-well plates are analysed on one 384-well ELISA and results may be analysed as follows:
First, MMP13 and MMP1 numeric data for each well are recalculated as percentage inhibition of the signal (% PIN) as follows:
%PIN=100−((signalsample−Av signalnon-triggered control)/(Av signalnegative controls−Av signalnon-triggered control)*100)
where,
-
- Av signalnon-triggered control is the average of non-triggered control of the 4 96-well plates all analysed on the same 384 ELISA
- Av signalnegative controls is the average of described negative controls of 4 96-well plates all analysed on the same 384 ELISA
TIMP2 results are expressed as percentage inhibition of the signal (% PIN) according to the following formula:
%PIN=100−((signalsample−Av signalbackground)/(Av signalnegative controls−Av signalbackground1)*100)
where
-
- Av signalbackground1 is the background signal of the TIMP2 ELISA i.e. signal obtained in absence of TIMP2
- Av signalnegative controls is the average of all negative controls of 4 96-well plates analysed on same 384 ELISA
Then, individual wells may be said to have a positive score if the % PIN was higher than 35% (for MMP1) or than 50% (MMP1). At these cutoff settings none of the negative controls are found to have a positive score. Results for transfections at 10 nM or 30 nM are given a scoring value of 1, only if both replicates are scoring above preset cutoffs. In order to assure that a drop in MMP1 or MMP13 expression is not caused by loss of cell viability, the TIMP2 results are taken into consideration. If TIMP2 signal is found to drop more than 35% for both replicates then result of MMP1 or MMP13 is not taken into account. For each screen a final value is assigned to the target that was the sum of the scoring values at both siRNA duplex test concentrations after taking into account the TIMP2 analysis. The effect of the siRNA duplex for a given gene is then believed to be a “true” effect if the sum of the final values of both screens is higher or equal to 2. The target is considered validated with synthetic siRNA if it scored as a true hit in either MMP1 or MMP13. As such, following targets were considered validated using the synthetic siRNA technology: ADAMTS6, MC3R, MET, CSNK1G2, EDG4, MAP4K1, KCNN4.
Taken together, the outcome of the on target validation exercise for the 13 hits selected through the on target analysis is indicated in Table 3. Nine targets were validated through the identification of an additional KD virus capable of recapitulating the effects of the original KD virus hit identified in the primary screen and 7 (3 of which were validated with an additional KD virus) were validated using the synthetic siRNA technology. Expression of these validated targets in primary human chondrocytes was further assessed (Example 5).
Example 5 Expression Analysis in Human Chondrocytes of the Preferred TargetsIn order to be validated as preferred targets, the genes should be expressed in chondrocytes. This may be assessed using quantitative real-time PCR. Normal human chondrocytes from articular cartilage (NHAC) (Cambrex, Verniers, Belgium) are seeded into 9 cm culture dishes at 3 million cells/dish in DMEM/F12 medium supplemented with 5% fetal calf serum (HighClone, Perbio, Erembodegem, Belgium). Two days later culture medium is replaced by either DMEM/F12 medium supplemented with 5% fetal calf serum, with or without 10 ng/mL of IL-1β, or with Chondrocyte differentiation medium (CDM, Cell Applications, San Diego, Calif.), with or without 10 ng/mL IL-1β. Each condition is performed in duplicate. After incubation for 48 h the medium is removed and cells are processed for RNA isolation using the RNeasy midi kit according to the manufacturer's instructions (Qiagen, Venlo Netherlands) and purified RNA is stored in aliquots at −20° C.
RNA is reverse transcribed to cDNA using the TaqMan® Gold RT kit (Applied Biosystems, Lennik, Belgium), according to the manufacturer's instructions (1× TaqMan® RT buffer, 5 mM MgCl2, 0.5 mM dNTP, 2.5 μM random hexamers, 10 U RNase inhibitor and 25 U multiscribe reverse transcriptase).
The cDNA is diluted 6-fold and 5 μL is used per PCR reaction in a 25 μL reaction for real-time QPCR in a ABI7000 instrument using either the SYBR® Green universal Mastermix or the TaqMan® Universal Mastermix (Both from Applied Biosystems).
For primer development in SYBR® Green QPCR analysis, DNA sequences are extracted from the RefSeq sequence depository, or, if not available, from the GenBank collection. From these sequences, primer pairs suitable for SYBR® Green QPCR are designed using the PrimerExpress software (Applied Biosystems). These primer pairs are checked for their specificity toward their target gene with the Blast software (NCBI, Entrez). Suitable primer pairs are ordered (Invitrogen) and used at 0.3 μM concentration. The primer pairs are shown in
Primer pair quality is monitored by melting point analysis, whereby pairs yielding more than one melting point are discarded, and by comparison to a reference cDNA (Clontech Laboratories, Mountain View, Calif.) whereby the difference in melting point should not differ by more than 1° C.
For the genes for which the SYBR® Green primer pair does not fulfill the requirements, a TaqMan® assay is used (Assay-on-demand, Applied Biosystems).
Genes are considered as expressed if the average Ct value over all conditions was 37 or less.
Expression of the preferred targets in human articular chondrocytes as obtained by quantitative real-time PCR. Each Ct value is the average of 8 independent RNA preparations of cells grown in 4 different conditions, as outlined in Example 5. The results are show in Table 5.
A Ct value of below 25 is considered high expression, between 25 and 30 is considered good expression, between 30 and 35 is considered moderate expression and above 35 is considered low expression. Therefore, good expression levels in primary chondrocytes could be demonstrated for most targets except for GPR34 (Ct=36), that displayed a low expression level. However, low expression levels may be observed for GPCRs and this low expression is not always predictive for low receptor activity
Example 6 Further Validation of EPHA5Exemplary foregoing TARGET EPHA5 has been validated and confirmed by compounds directed against EPHA5 which inhibit EPHA5 and also inhibit MMP13 activity in NHACs. The activity against EPHA5 may be tested using the assays as described in Examples 6.1 and 6.2 below, ability to inhibit MMP13 activity in NHACs may be tested as described in Example 7.
6.1 EPHA5 Inhibition—Biochemical AssayRecombinant Epha5 (Millipore catalog number 14-639) is incubated with 0.1 mg/mL Poly(Glu,Tyr)sodium salt (4:1), MW 20 000-50 000 (Sigma catalog number P0275) in kinase reaction buffer (10 mM MOPS pH7.0, 1 mM DTT, 0.01% Trition-X100, 2.5 mM MnCl2, 0.5 mM Na3VO4, 5 mM beta-glycerolphosphate, 0.5 μM non-radioactive ATP, 0.25 μCi 33P-gamma-ATP (Perkin Elmer, catalog number NEG602K) final concentrations with or without 5 μL containing test compound or vehicle (DMSO, 1% final concentration), in a total volume of 25 μL in a polypropylene 96-well plate (Greiner, V-bottom). After 45 min at 30° C., reactions are stopped by adding 25 μL/well of 150 mM phosphoric acid. All of the terminated kinase reaction is transferred to prewashed (75 mM phosphoric acid) 96 well filter plates (Perkin Elmer catalog number 6005177) using a cell harvester (Perkin Elmer). Plates are washed 6 times with 300 μL per well of a 75 mM phosphoric acid solution and the bottom of the plates is sealed. 40 μL/well of Microscint-20 is added, the top of the plates is sealed and readout is performed using the Topcount (Perkin Elmer). Kinase activity is calculated by subtracting counts per minute (cpm) obtained in the presence of a positive control inhibitor (10 μM staurosporine) from cpm obtained in the presence of vehicle. The ability of a test compound to inhibit this activity is determined as:
Percentage inhibition=((cpm determined for sample with test compound present−cpm determined for sample with positive control inhibitor) divided by (cpm determined in the presence of vehicle−cpm determined for sample with positive control inhibitor))*100%.
Dose dilution series are prepared for the compounds enabling the testing of dose-response effects in the EPHA5 assay and the calculation of the IC50 for each compound. Each compound is routinely tested at concentration of 30 μM followed by a ⅓ serial dilution, 8 points (30 μM-6.67 μM-2.22 μM-740 nM-247 nM-82 nM-27 nM-9 nM) in a final concentration of 1% DMSO. If potency of compound series is increased, more dilutions may be prepared and/or the top concentration may be lowered (e.g. 5 μM, 1 μM).
6.2 EPHA5 Inhibition—Cell AssayThe assay principle is to determine inhibitor activity on the STAT3 (Tyr705) phosphorylation level in HEK293 cells transiently transfected with STAT3 and EPHA5.
HEK293 are maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% heat inactivated fetal calf serum, 100 U/mL Penicillin and 100 μg/mL Streptomycin.
HEK293 at 70% confluency are collected by standard trysinisation. 15,000,000 cells are transiently transfected with 6,250 ng of pIPspAdapt6-STAT3, 3,750 ng of pIPspAdapt6-EPHA5, 4,000 ng of pIPspAdapt6-eGFP and 11,000 ng of pBSK using 50 μL Jet-PEI (Polyplus) as transfection reagent per T175 cm2 cell culture flask. The transfected cells are seeded in T175 cm2 cell culture flask. After overnight incubation at 37° C., 10% CO2, transfection medium is removed and fresh cell culture medium is carefully added to avoid cell detachment.
48 hour after transfection, medium is removed. Cells are detached with prewarmed cell dissociation solution (Sigma cat no. C5914). 60,000 cells/40 μL of DMEM are seeded per well in 384-well plate. Then 10 μL of compound dilution (5×) in DMEM is added.
All compounds are tested in duplicate starting from 20 μM followed by a ⅓ serial dilution, 8 points (20 μM-6.6 μM-2.2 μM-740 nM-250 nM-82 nM-27 nM-9 nM) in a final concentration of 0.2% DMSO.
After 5 h incubation at 37° C., phosphor-Stat3 (Tyr705) levels are determined using the AlphaScreen® SureFire® Phospho-STAT 3 (Tyr705) Assay Kit (From Perkin Elmer). Cells are lysed by addition of 15 μL of 1× lysis buffer. The plate is gently shaken for 20 min at room temperature, 4 μL of lysate is transferred to the proxiplate, then 7 μL reaction buffer/activation buffer mix containing alpha-beads are added and the plate is sealed with an aluminium seal, shaken for 5 minutes and incubated for 16 hours at RT in the dark.
The plates are read on the Envision using standard AlphaScreen settings. 0.2% DMSO is used as a negative control (0% inhibition). The positive and negative controls are used to calculate z′ and PIN values.
Percentage inhibition=(1−((value determined for sample with test compound present−value determined for sample with positive control inhibitor) divided by (value determined in the presence of vehicle−value determined for sample with positive control inhibitor)))*100%.
Compounds identified as being active against one of the TARGETs identified herein, may be directly tested in an MMP13 inhibition assay.
Normal human articular chondrocytes (NHAC, Lonza cat no CC-2550) are suspended at a concentration of 1 600 000 cells per mL in medium (Gibco, DMEM: F12) containing 5% FBS and 1% pen/strep. 25 μL of the cell suspension is then pooled with 25 μL 0.8% agarose in medium with 5% serum and 1% pen/strep and added to a well of a 96-well culture dish precoated with 50 μL 1.5% agarose in medium with 5% serum and 1% pen/strep. After the agarose has set, 127.5 μL medium is added to each well. The cells are then treated with 7.5 μL compound at various concentrations for 1 hour followed by triggering with 15 μL 10 ng/mL IL-1b (final concentration: 1 ng/mL). 48 hours after triggering, the supernatant is harvested and MMP13 secretion is measured. Each compound is routinely tested at concentration of 30 μM followed by a ⅓ serial dilution, 8 points (30 μM-10 μM-3.33 μM-1.11 μM-370 nM-123 nM-41 nM-14 nM) in a final concentration of 0.3% DMSO.
MMP13 activity is measured in an antibody capture activity assay. For this purpose, 384 well plates (NUNC, P6491, MaxiSorp black) are coated with 35 μL of a 1.5 μg/mL anti-human MMP13 antibody (R&D Systems, MAB511) solution for 24 hours at 4° C. After washing the wells 2 times with PBS+0.05% Tween, the remaining binding sites are blocked with 100 μL 5% non-fat dry milk (Santa Cruz, sc-2325, Blotto) in PBS for 24 hours at 4° C. Then, the wells are washed 2 times with PBS+0.05% Tween and 35 μL culture supernatant containing MMP13 is added and incubated for 4 hours at room temperature. Following this the wells are washed 2 times with PBS+0.05% Tween and MMP13 protein is then fully activated by addition of 35 μL of a 1.5 mM 4-Aminophenylmercuric acetate (APMA) (Sigma, A9563) solution and incubation at 37° C. for 1 hour. Then, the wells are washed again with PBS+0.05% Tween and 35 μL MMP13 substrate (Biomol, P-126, OmniMMP fluorogenic substrate) is added. After incubation for 1 hour at 37° C. fluorescence of the converted substrate is measured in a Perkin Elmer Wallac EnVision 2102 Multilabel Reader (wavelength excitation: 320 nm, wavelength emission: 405 nm).
Percentage inhibition=((fluorescence determined in the presence of vehicle−fluorescence determined for sample with test compound present) divided by (fluorescence determined in the presence of vehicle−fluorescence determined for sample without trigger))*100%.
The activity of compounds against GPR43 may be tested using the assays as described Example 8 or 9 below
Example 8 GPR43 Phenotypic Assay—Neutrophil Migration Assay8.1 Isolation of Neutrophils from Buffy Coats
A human buffy coat is diluted with an equal volume of ice cold DPBS (Invitrogen cat#14190169). 20 mL of diluted buffy coat down is gently mixed with 4 mL of 140 mM citric acid, 200 mM sodium citrate and 220 mM Dextrose in a 50 mL conical tube. 12 mL of a 6% Dextran/0.9% NaCl solution (WN) in water is added gently and mixed by inverting the tube up to 20 times. The total volume is then transferred to a fresh tube and incubated at room temperature for 1 hour for complete separation of the two phases. The yellow supernatant is then transferred to a new tube and centrifuged at 1300 rpm for 12 minutes in a standard table top centrifuge at 4° C. without brake. The supernatant is discarded and the remaining cell pellet is rapidly resuspended by pipetting up and down in 12 mL of ice-cold water. After 20 seconds 4 mL of ice cold 0.6 M KCl is added, mixed carefully and centrifuged at 1300 rpm for 12 minutes in a standard table top centrifuge at 4° C. without brake. This procedure is repeated until no red blood cells remain. Finally the pellet is resuspended in 4 mL of DPBS and layered over 5 mL of Lymphoprep™ (Nycomed Pharma, Cat#1114545) in a 15 mL tube. After centrifugation at 1300 rpm for 12 minutes in a standard table top centrifuge at 4° C. with low brake, the supernatant is removed and the cell pellet is resuspended in 25 mL chemotaxis buffer (RPMI 1640 (Invitrogen, Cat#21875) supplemented with 10 mM of HEPES (Invitrogen, Cat#15630).
8.2 Migration AssayThe migration assay is performed in a Corning HTS transwell 96 permeable support system with 5.0 μM pore size polycarbonate membrane (Corning Cat#3387). 180 μL of a cell suspension of 8.9×106 cells/mL is added to 20 μL of compound solution in chemotactic buffer in a polypropylene 96-well V-bottom plate. The cells are incubated for 30 minutes with an intermediate resuspension after 15 minutes to prevent the cells from settling to the plate bottom. Following this the 70 μL cell suspension is transferred to the upper compartment of the transwell system. The receiver well is filled with 200 μL chemotaxis buffer containing compound and chemotactic agent. After incubation at 37° C. in 5% CO2 for 1 hour, the amount of cells that migrate to the receiver plate is measured by lysis and measuring ATP content of the lysate using ATP-lite (Promega, Cat#6016739) in a luminometer.
8.3 Data AnalysisCompound effects are expressed as percent inhibition using the formula:
[(RLU in the presence of vehicle & chemotactic agent−RLU in presence of compound & chemotactic agent)/(RLU in the presence of vehicle & chemotactic agent−RLU in absence of chemotactic agent)]*100
RLU=relative luminescence units.
Example 9 GPR43—Calcium Flux AssayThe activity against GPR43 may be tested using the assay as described in below
Clear bottom 384 well plates (Corning, ref 3712) are coated with 25 μL poly-D-Lysine (Sigma, ref P-6407) diluted in PBS at a final concentration of 0.05 mg/mL and incubated for 30 minutes at 37° C. Polylysine is removed by 2 washes with PBS. Six thousand HEK293 cells are seeded in 25 μL of DMEM complemented with 10% FBS, 10 μg/mL puromycin and 1% penicillin/streptomycin. The plates are then incubated for 24 hours at 37° C./5% CO2. Twenty-five μL of calcium 4 dye (Molecular devices, ref. R8141) are added to plates according to manufacturer instructions and plates are incubated for 2 hours 15 minutes at 37° C./5% CO2. Ten μL of compound solutions in HBSS, 20 mM hepes are then added and plates are incubated at 37° C./5% CO2 for 15 minutes. Antagonist activity is measured by adding 10 μL of sodium acetate (Sigma, ref 52889) in HBSS, 20 mM hepes at the EC80 concentration.
Calcium signaling is measured using a Flex station3 (Molecular Devices) by recording fluorescence (excitation 485 nm, emission 525 nm) during sixty seconds. Activity is determined as the ration between the maximal fluorescence of the calcium curves produced by the sodium acetate and the basal fluorescence measured before sodium acetate addition. Percentages of inhibition are calculated using negative (vehicle addition) and positive (sodium acetate at EC100) controls on each plate.
Example 10 EDG4 Calcium Flux AssayThe activity of compounds against EDG4 may be tested using the assay as described below
Ten thousand CHO-EDG4 cells per well are resuspended in 50 μL of DMEM/F12 complemented with 10% FBS and 10 μg/mL Puromycin, then are seeded in clear bottom 384 well plates (Corning, ref 3712). After 24 hours incubation at 37° C./5% CO2 plates are washed twice with 25 μL of DMEM/F12 complemented with 0.1% fatty acid free BSA and then plates are incubated for 1 hour at 37° C./5% CO2. Twenty-five μL of Fluo 4 Direct Ca dye (Invitrogen, ref F10473) diluted in HBSS containing calcium and magnesium (Gibco ref 14025) complemented with 20 mM HEPES (with further ½ dilution compared to manufacturer instructions), and 5 mM Probenicid (Invitrogen, ref P36400) are added to the plates. Plates are then incubated for 1 hour at 37° C./5% CO2. Ten μL of compound solutions in HBSS, 20 mM hepes, 0.1% fatty acid free BSA, 0.6% DMSO are then added and plates are incubated at 37° C./5% CO2 for 15 minutes. Antagonist activity is measured by adding 10 μL of oleoyl-L-Lysophosphatidic acid sodium salt (LPA, Sigma, ref L7260) in HBSS, 20 mM hepes, 0.1% fatty acid free BSA at the EC80 concentration.
Calcium signaling is measured using a Flex station3 (Molecular Devices) by recording fluorescence (excitation 485 nm, emission 525 nm) for sixty seconds. Activity is determined as the ratio between the maximal fluorescence of the calcium curve produced by the LPA and the basal fluorescence measured before LPA addition. Percentages of inhibition are calculated using negative (vehicle addition) and positive (LPA at EC100) controls on each plate.
The activity of compounds against CSNK1G2 may be tested using the assay as described in Example 11 or 12 below.
Example 11 CSNK1G2 Biochemical Assay0.75 mU of recombinant CSNK1G2 (Millipore catalog number 14-712) is incubated with 0.1 mg/mL casein (Sigma catalog number C4765) in kinase reaction buffer (10 mM MOPS pH7.0, 0.01% Triton-X-100, 0.5 mM EDTA, 1 mM DTT, 0.5 mM Na3VO4, 5 mM beta-glycerophosphate, 10 mM MgCl2, 0.5 μM non-radioactive ATP, 0.25 μCi 33P-gamma-ATP (Perkin Elmer, catalog number NEG602K) final concentrations with or without 5 μL containing test compound or vehicle (DMSO, 1% final concentration), in a total volume of 25 μL in a polypropylene 96-well plate (Greiner, V-bottom). After 45 min at 30° C., reactions are stopped by adding 25 μL/well of 150 mM phosphoric acid. All of the terminated kinase reaction is transferred to prewashed (75 mM phosphoric acid) 96 well filter plates (Perkin Elmer catalog number 6005177) using a cell harvester (Perkin Elmer). Plates are washed 6 times with 300 μL per well of a 75 mM phosphoric acid solution and the bottom of the plates is sealed. 40 μL/well of Microscint-20 is added, the top of the plates is sealed and readout is performed using the Topcount (Perkin Elmer).
Kinase activity is calculated by subtracting counts per minute (cpm) obtained in the presence of a positive control inhibitor (20 μM staurosporine) from cpm obtained in the presence of vehicle. The ability of a test compound to inhibit this activity is determined as:
Percentage inhibition=((cpm determined for sample with test compound present−cpm determined for sample with positive control inhibitor) divided by (cpm determined in the presence of vehicle−cpm determined for sample with positive control inhibitor))*100%.
Dose dilution series are prepared for the compounds enabling the testing of dose-response effects in the CSNK1G2 assay and the calculation of the IC50 for each compound. Each compound is routinely tested at concentration of 30 μM followed by a ⅓ serial dilution, 8 points (30 μM-6.67 μM-2.22 μM-740 nM-247 nM-82 nM-27 nM-9 nM) in a final concentration of 1% DMSO. If potency of compound series is increased, more dilutions may be prepared and/or the top concentration may be lowered (e.g. 5 μM, 1 μM).
Example 12 CSNK1G2 Cell AssayIn the Wnt-signaling assay a Wnt luciferase reporter construct is transfected together with expression vectors for LRP6 and CSNK1G2 into SW1353 cells with the JetPEI transfection agent (Polyplus Transfection, Cat no 101-40). CSNK1G2 overexpression potentiates LRP6-induced Wnt-reporter activity. The CSNK1G2- and LRP6-mediated expression of the luciferase reporter gene is measured with a luciferase substrate. Compounds inhibiting CSNK1G2 activity will reduce reporter activity.
Day 1: a suspension of SW1353 cells is prepared (density: 30000 cells/well/80 μL (375000 cells/mL)). In parallel, a DNA/transfection agent mixture is prepared as follows.
The total amount of DNA to be added per well is diluted to 10 μL in a NaCl 150 mM solution. Typically, following amounts of DNA will be transfected per well: Wnt-luc reporter (20 ng), A010800-CSNK1G2-WT (20 ng), pCS-myc-hLRP (10 ng). The total amount of JetPEI transfection agent needed per well (0.32 μL) is diluted to 10 μL in a NaCl 150 mM solution. JetPEI solution and DNA solutions are then mixed yielding 20 μL DNA/transfection agent mix to be added per well. This solution is immediately mixed, centrifuged and incubated for 30 min at RT. The cell suspension is added dropwise to the DNA/transfection agent mix, and incubated at 37° C. for 2 hrs. The compound to be tested, diluted to 11 μL, is then added to the wells containing the transfected cells using an automated dispenser (Tecan aquarius) and the mixture is incubated for 16 to 24 hours.
Day 2: The medium on top of the cells is removed and the luciferase substrate SteadyLite HTS (Perkin Elmer, CatNo 550-070303) is then added to the white 96-well plates (50 μL/well). After an incubation of 30 min in the dark under continuous shaking, the readout is performed readout with a luminometer (Envision, Perkin Elmer).
REFERENCES
- Appleton C T, Pitelka V, Henry J, Beier F, Global analyses of gene expression in early experimental osteoarthritis, Arthritis Rheum. 2007; 56(6):1854-68.
- Billinghurst, R C, et al., Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum. 2000; 43:664-672.
- Billinghurst, R C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest. 1997; 99:1534-1545.
- Boerner. P, Lafond, R, Lu, W Z, Brams, P, and Royston, I, Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes, J. Immunol., 1991, 147(1):86-95.
- Cao, Z; Xiong, J; Takeuchi, M; Kurama, T; Goeddel, D V, TRAF6 is a signal transducer for interleukin-1. Nature 383: 443-446, 1996.
- Chen, C J, Banerjea, A C, Harmison, G G, Haglund, K, Schubert, M, Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication—potential effectiveness against most presently sequenced HIV-1 isolates Nucl. Acids Res. 1992 20: 4581-4589;
- Choy E H, Panayi G S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J. Med. 2001; 344(12):907-16.
- Clegg D O, Reda D J, Harris C L, Klein M A, O'Dell J R, Hooper M M, Bradley J D, Bingham C O 3rd, Weisman M H, Jackson C G, Lane N E, Cush J J, Moreland L W, Schumacher H R Jr, Oddis C V, Wolfe F, Molitor J A, Yocum D E, Schnitzer T J, Furst D E, Sawitzke A D, Shi H, Brandt K D, Moskowitz R W, Williams H J. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J. Med. 2006; 354(8):795-808.
- Cole, et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77;
- Dahlberg, L, et al. Collagenase-mediated cleavage of type II collagen is selectively enhanced in osteoarthritis cartilage and can be arrested with a synthetic inhibitor which spares collagenase-1 (MMP-1). Arthritis Rheum. 2000; 43:673-682.
- Firestein G S. Evolving concepts of rheumatoid arthritis, Nature. 2003; 423(6937):356-61.
- Gao, X and Huang, L, Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes, Nucl. Acids Res. 1993 21: 2867-2872
- Hoogenboom and Winter, By-passing immunisation: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J. Mol. Biol. 1992, 227:381-8;
- Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol. Chem. 1999 Sep. 24; 274(39):27339-42. Review.
- Kashani-Sabet, et al., Reversal of the malignant phenotype by an anti-ras ribozyme Antisense Res Dev, 1992 2:3-15
- Lee D M, Weinblatt M E. “Rheumatoid arthritis” Lancet. 2001; 358(9285):903-11.
- Lipinski C A, Lombardo F, Dominy B W and Feeney P J., “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings” Adv Drug Deliv Rev, 2001; 46: 3-26
- Mark and Padlan, (1994) “Chapter 4. Humanization of Monoclonal Antibodies”, The Handbook of Experimental Pharmacology Vol. 113, Springer-Verlag, New York
- Marks J D, Hoogenboom H R, Bonnert T P, McCafferty J, Griffiths A D, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol. Biol. 1991 Dec. 5; 222(3):581-97 Links
- Milstein and Cuello, Hybrid hybridomas and their use in immunohistochemistry Nature 1983, 305:537-9 Mitchell, P G, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest. 1996; 97:761-768.
- Neuhold L A, Killar L, Zhao W, Sung M L, Warner L, Kulik J, Turner J, Wu W, Billinghurst C, Meijers T, Poole A R, Babij P, DeGennaro L J J; Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. Clin Invest. 2001 January; 107(1):35-44.
- O'Dell J R. Therapeutic strategies for rheumatoid arthritis., N Engl J. Med. 2004; 350(25):2591-602.
- Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs, Nat. Methods. 2006; 3(9):670-6.
- Schmidt M R, Piekos B, Cabatingan M S, Woodland R T. Expression of a human coxsackie/adenovirus receptor transgene permits adenovirus infection of primary lymphocytes. J. Immunol. 2000 165:4112-9.
- Shlopov, B V, et al. Osteoarthritic lesions. Involvement of three different collagenases. Arthritis Rheum. 1997; 40:2065-2074.
- Smolen J S, Steiner G. Therapeutic strategies for rheumatoid arthritis, Nat Rev Drug Discov. 2003; 2(6):473-88.
- Traunecker A, Lanzavecchia A, Karjalainen K Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells, EMBO J. 1991; 10(12):3655-9.
- Ventura M, Wang P, Ragot T, Perricaudet M, Saragosti S. Activation of HIV-specific ribozyme activity by self-cleavage, Nucleic Acids Res. 1993; 21(14):3249-55.
- Wieland H A, Michaelis M, Kirschbaum B J, Rudolphi K A. “Osteoarthritis—an untreatable disease?”, Nat Rev Drug Discov. 2005; 4(4):331-44.
- Wu W, Billinghurst R C, Pidoux I, Antoniou J, Zukor D, Tanzer M, Poole A R, Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum. 2002 August; 46(8):2087-94.
Claims
1. A method for identifying a compound that inhibits ECM and/or cartilage degradation, comprising:
- (a) contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 40, 27, 42, 22-26, 28-38, and 41 and fragments thereof; and
- (b) measuring a compound-polypeptide property related to ECM and/or cartilage degradation.
2. The method according to claim 1, wherein said polypeptide is in an in vitro cell-free preparation.
3. The method according to claim 1, wherein said polypeptide is present in a mammalian cell.
4. The method of claim 2, wherein said property is a binding affinity of said compound to said polypeptide.
5. The method of claim 1, wherein the method is used to identify compounds that inhibit the catabolic process of chondrocytes.
6. The method of claim 4, which additionally comprises the steps of:
- c) contacting a population of mammalian cells expressing said polypeptide with the compound that exhibits a binding affinity of at least 10 micromolar; and
- d) identifying a compound that inhibits ECM and/or cartilage degradation.
7. The method of claim 1, wherein said property is the expression and/or activity of MMP1, MMP3, MMP8, MMP13, MMP14, and/or ADAMTS4.
8. The method of claim 7, wherein said property is the expression and/or activity of MMP13.
9. The method according to claim 1, wherein said property is the activity of said polypeptide.
10. The method according to claim 1, wherein said property is the expression of said polypeptide.
11. The method according to claim 9, which additionally comprises the steps of:
- c) contacting a population of mammalian cells expressing said polypeptide with the compound that significantly inhibits the expression or activity of the polypeptide; and
- d) identifying the compound that inhibits ECM and/or cartilage degradation.
12. The method according to claim 1, which additionally comprises the step of comparing the compound to be tested to a control.
13. The method according to claim 12, wherein said control is where the polypeptide has not been contacted with said compound.
14. The method according to claim 6, which additionally comprises the step of comparing the compound to a control, wherein said control is a population of mammalian cells that does not express said polypeptide.
15. The method according to claim 1, wherein said compound is selected from the group consisting of compounds of a commercially available screening library and compounds having binding affinity for a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 40, 27, 42, 22-26, 28-38, and 41.
16. The method according to claim 1, wherein said compound is a peptide in a phage display library or an antibody fragment library.
17. An agent effective in inhibiting ECM and/or cartilage degradation, selected from the group consisting of an antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA), wherein said agent comprises a nucleic acid sequence complementary to, or engineered from, a naturally-occurring polynucleotide sequence of about 17 to about 30 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 18, 19, 6, 21, 1-5, 7-17, and 20.
18. (canceled)
19. (canceled)
20. (canceled)
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. (canceled)
26. (canceled)
27. A pharmaceutical composition comprising a therapeutically effective amount of an agent according to claim 17 in admixture with a pharmaceutically acceptable carrier.
28. (canceled)
29. (canceled)
30. (canceled)
31. A method for treatment and/or prevention of a pathological condition involving ECM and/or cartilage degradation in a subject comprising administering to said subject a therapeutically effective amount of agent selected from the group consisting of an agent having binding affinity with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 39, 40, 27, 42, 22-26, 28-38, and 41 and fragments thereof, and an antisense polynucleotide, a ribozyme, and a small interfering RNA (siRNA) comprising a nucleic acid sequence complementary to, or engineered from, a naturally-occurring polynucleotide sequence of about 17 to about 30 contiguous nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 18, 19, 6, 21, 1-5, 7-17, and 20.
32. A method for diagnosing a pathological condition involving ECM and/or cartilage degradation, comprising determining a first amount or activity of polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:39, 40, 27, 42, 22-26, 28-38, and 41 present in a biological sample obtained from said subject, and comparing said first amount or activity with the ranges of amounts or activities of the polypeptide determined in a population of healthy subjects, wherein an increase of the amount or activity of polypeptide in said biological sample compared to the range of amounts or activities determined for healthy subjects is indicative of the presence of the pathological condition.
33. The method of claim 31 wherein the pathological condition is osteoarthritis.
34. The method of claim 32 wherein the pathological condition is osteoarthritis.
Type: Application
Filed: Jan 24, 2014
Publication Date: Jul 17, 2014
Inventors: Reginald Christophe Xavier Brys (Mechelen), Luc Nelles (Mechelen), Nick Ernest Rene Vandeghinste (Mechelen), Blandine Mille-Baker (CR Leiden), Michela Angela Tessari (CR Leiden)
Application Number: 14/162,908
International Classification: G01N 33/50 (20060101); C12N 15/113 (20060101);
